@article{MTMT:34444102, title = {10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024}, url = {https://m2.mtmt.hu/api/publication/34444102}, doi = {10.2337/dc24-S010}, journal-iso = {DIABETES CARE}, journal = {DIABETES CARE}, volume = {47}, unique-id = {34444102}, issn = {0149-5992}, abstract = {The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an in-terprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA stand-ards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. © 2023 by the American Diabetes Association.}, year = {2024}, eissn = {1935-5548}, pages = {S179-S218} } @article{MTMT:34582822, title = {Therapy of heart failure with reduced pump function}, url = {https://m2.mtmt.hu/api/publication/34582822}, author = {Abdin, Amr and Boehm, Michael}, doi = {10.1055/a-2054-9636}, journal-iso = {DEUT MED WOCHENSCHR}, journal = {DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT}, volume = {149}, unique-id = {34582822}, issn = {0012-0472}, abstract = {HFrEF causes significant morbidity and mortality and represents a major public health burden. Recently, there have been significant scientific advances in the treatment of HFrEF, with ARNI, BB, MRA, and SGLT-2i forming the GDMT for HFrEF. Basic quadruple therapy has been shown to significantly reduce of HF hospitalizations, all-cause mortality, and cardiovascular mortality. In addition, new initiation and titration procedures have recently been introduced that may progressively improve the management and prognosis of HFrEF. Further efforts are also needed to improve the use of GDMT, which is currently underutilized.}, keywords = {Therapy; heart failure; Device therapy; GDMT}, year = {2024}, eissn = {1439-4413}, pages = {157-165} } @article{MTMT:34623850, title = {Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis}, url = {https://m2.mtmt.hu/api/publication/34623850}, author = {Aldafas, Rami and Crabtree, Tomas and Alkharaiji, Mohammed and Vinogradova, Yana and Idris, Iskandar}, doi = {10.1093/ageing/afad254}, journal-iso = {AGE AGEING}, journal = {AGE AND AGEING}, volume = {53}, unique-id = {34623850}, issn = {0002-0729}, keywords = {heart failure; systematic review; Type 2 diabetes; OLDER; Older people; sodium-glucose cotransporter 2 inhibitors; frail}, year = {2024}, eissn = {1468-2834} } @article{MTMT:34728497, title = {The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis}, url = {https://m2.mtmt.hu/api/publication/34728497}, author = {Ali, M.U. and Mancini, G.B.J. and Fitzpatrick-Lewis, D. and Connelly, K.A. and O’Meara, E. and Zieroth, S. and Sherifali, D.}, doi = {10.1186/s12933-024-02154-w}, journal-iso = {CARDIOVASC DIABETOL}, journal = {CARDIOVASCULAR DIABETOLOGY}, volume = {23}, unique-id = {34728497}, issn = {1475-2840}, abstract = {Background: The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) use. Since then, additional trials of relevance for SGLT2i have been published. This update re-evaluates the clinical recommendations for using SGLTi and their indirect comparison with existing evidence on GLP-1RA as compared to the standard of care to reduce cardiorenal morbidity and mortality. Methods: We updated our existing search and screening of the literature from September 2021 to April 2023 for randomized controlled trials of SGLT2i and GLP-1RA with placebo control. We conducted risk of bias assessment, data extraction and updated our meta-analysis of studies with similar interventions and components. The certainty of the evidence was determined using GRADE. Results: Evidence from three new trials and additional results from an updated existing trial on SGLT2i met our inclusion criteria after an updated search. Across all the included studies, the total sample size was 151,023 adults, with 90,943 in SGLT2i trials and 60,080 in GLP-1 RA trials. The mean age ranged from 59.9 to 68.4 years. Compared with standard care, the use of SGLT2i and GLP-1 RA showed significant reductions in the outcomes of cardiovascular (CV) mortality (14% & 13%), any-cause mortality (12% & 12%), major adverse CV events (MACE) (11% & 14%), heart failure (HF) hospitalization (30% & 9%), CV death or HF hospitalization (23% & 11%), and kidney composite outcome (32% & 22%). In participants with T2D, both classes demonstrated significant cardiorenal protection. But, only GLP-1RA showed a reduction in non-fatal stroke (16%) and only SGLT2i showed a reduction in HF hospitalization (30%) in this population of people living with T2D. Conclusions: This updated and comprehensive meta-analysis substantiates and strengthens the clinical recommendations of the CCS cardiorenal guidelines. © The Author(s) 2024.}, keywords = {Aged; Aged; Adult; Adult; Middle Aged; Middle Aged; Humans; SODIUM; SODIUM; MORTALITY; review; human; Treatment Outcome; Canada; Canada; GLUCOSE; GLUCOSE; hospitalization; cerebrovascular accident; Meta-analysis; heart failure; heart failure; heart failure; cardiovascular diseases; Diabetes Mellitus, Type 2; cardiovascular disease; Hypoglycemic Agents; antidiabetic agent; drug efficacy; chronic kidney failure; systematic review; meta analysis; morbidity; renal protection; patient care; heart protection; evidence based medicine; non insulin dependent diabetes mellitus; non insulin dependent diabetes mellitus; Cardiovascular mortality; groups by age; Symporters; glucagon like peptide 1; Glucagon-Like Peptide 1; glucagon like peptide 1 receptor agonist; cotransporter; Glucagon-like peptide-1 receptor; glucagon like peptide 1 receptor; glucagon-like peptide-1 receptor agonists; major adverse cardiac event; Sodium-glucose co-transporter 2 inhibitors; Sodium glucose cotransporter 2 inhibitor; cardiorenal outcomes}, year = {2024}, eissn = {1475-2840} } @article{MTMT:34766677, title = {CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure}, url = {https://m2.mtmt.hu/api/publication/34766677}, author = {Allen, L.A.}, doi = {10.1016/j.jchf.2024.02.010}, journal-iso = {JACC HEART FAILURE}, journal = {JACC-HEART FAILURE}, volume = {12}, unique-id = {34766677}, issn = {2213-1779}, keywords = {human; Survival Rate; Quality of Life; Quality of Life; editorial; Health Status; heart failure; heart failure; drug efficacy; patient care; heart left ventricle ejection fraction; heart failure with reduced ejection fraction; Canagliflozin; enkephalinase inhibitor; sodium glucose cotransporter inhibitor}, year = {2024}, eissn = {2213-1787}, pages = {719-721} } @article{MTMT:34536415, title = {Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis}, url = {https://m2.mtmt.hu/api/publication/34536415}, author = {Al, Namat R. and Duceac, L.D. and Chelaru, L. and Dabija, M.G. and Guțu, C. and Marcu, C. and Popa, M.V. and Popa, F. and Bogdan, Goroftei E.R. and Țarcă, E.}, doi = {10.3390/diagnostics14010016}, journal-iso = {DIAGNOSTICS}, journal = {DIAGNOSTICS}, volume = {14}, unique-id = {34536415}, issn = {2075-4418}, abstract = {Introduction: Increasingly, SGLT2 inhibitors save patients with heart failure and comorbidities such as type-2 diabetes mellitus (T2DM) and chronic kidney disease (CKD); the inhibition of sodium-glucose cotransporter 2 (SGLT2) was first studied in patients with diabetes as a solution to lower glucose levels by preventing glucose reabsorption and facilitating its elimination; in the process, researchers took notice of how SGLT2 inhibitors also seemed to have beneficial cardiovascular effects in patients with both diabetes and cardiovascular disease. Aim: Our single-center prospective study assesses outcomes of post-coronary artery bypass grafting (CABG) rehabilitation and SLGT2 inhibition in CABG patients with/without T2DM and with/without CKD. Materials and Methods: One hundred twenty consecutive patients undergoing CABG were included in the analysis. Patients were divided into four subgroups: diabetes patients with chronic kidney disease (T2DM + CKD), diabetes patients without chronic kidney disease (T2DM−CKD), prediabetes patients with chronic kidney disease (PreD+CKD), and prediabetes patients without chronic kidney disease (PreD−CKD). Echocardiographic and laboratory investigations post-surgery (phase I) and 6 months later (phase II) included markers for cardiac ischemia, glycemic status, and renal function, and metabolic equivalents were investigated. Results: One hundred twenty patients participated, mostly men, overweight/obese, hypertensive, smokers; 65 had T2DM (18 with CKD), and 55 were prediabetic (17 with CKD). The mean ejection fraction increased by 8.43% overall but significantly more in the prediabetes group compared to the T2DM group (10.14% vs. 6.98%, p < 0.05). Overall, mean heart-type fatty-acid-binding protein (H-FABP) levels returned to normal levels, dropping from 68.40 ng/mL to 4.82 ng/mL (p = 0.000), and troponin data were more nuanced relative to an overall, strongly significant decrease of 44,458 ng/L (p = 0.000). Troponin levels in patients with CKD dropped more, both in the presence of T2DM (by 82,500 ng/L, p = 0.000) and in patients without T2DM (by 73,294 ng/L, p = 0.047). As expected, the overall glycated hemoglobin (HbA1c) levels improved significantly in those with prediabetes (from 6.54% to 5.55%, p = 0.000); on the other hand, the mean HbA1c changed from 7.06% to 6.06% (p = 0.000) in T2DM, and the presence or absence of CKD did not seem to make any difference: T2DM+CKD 7.01–6.08% (p = 0.000), T2DM−CKD 7.08–6.04% (p = 0.000), PreD+CKD 5.66–4.98% (p = 0.014), and PreD−CKD 6.03–4.94% (p = 0.00). Compared to an overall gain of 11.51, the GFRs of patients with CKD improved by 18.93 (68.15–87.07%, p = 0.000) in the presence of established diabetes and 14.89 (64.75–79.64%, p = 0.000) in the prediabetes group. Conclusions: Regarding the patients’ cardiac statuses, the results from our single-center analysis revealed a significant decrease in ischemic risk (H-FABP and hs-cTnI levels) with improvements in mean ejection fraction, glycemic status, and renal function in patients post-CABG with/without T2DM, with/without CKD, and with SGLT2 inhibitor dapagliflozin treatment while undergoing cardiac rehabilitation. © 2023 by the authors.}, keywords = {heart failure; Type-2 diabetes mellitus; CABG; SGLT2 inhibitors; H-FABP}, year = {2024}, eissn = {2075-4418} } @article{MTMT:34517163, title = {11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024}, url = {https://m2.mtmt.hu/api/publication/34517163}, author = {American, Diabetes Association Professional Practice Committee}, doi = {10.2337/dc24-S011}, journal-iso = {DIABETES CARE}, journal = {DIABETES CARE}, volume = {47}, unique-id = {34517163}, issn = {0149-5992}, abstract = {The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. © 2023 by the American Diabetes Association.}, keywords = {Body Weight; Humans; ARTICLE; POTASSIUM; human; diabetes mellitus; diabetes mellitus; diabetes mellitus; disease duration; GLYCEMIC CONTROL; HYPERTENSION; Smoking Cessation; standard; physical activity; United States; Reference Standards; Societies, Medical; ENDOCRINOLOGY; ENDOCRINOLOGY; risk management; albumin; microalbuminuria; diabetic nephropathy; dipeptidyl carboxypeptidase inhibitor; cardiovascular disease; insulin dependent diabetes mellitus; placebo; antidiabetic agent; creatinine; chronic kidney failure; chronic kidney failure; creatinine blood level; Internet; medical society; health care quality; patient monitoring; access to information; practice guideline; urinalysis; renal protection; risk reduction; patient care; heart protection; drug contraindication; acute kidney failure; evidence based practice; angiotensin receptor antagonist; non insulin dependent diabetes mellitus; Cardiovascular risk; professional practice; patient referral; protein intake; metformin; blood pressure regulation; Renal Insufficiency, Chronic; hyperkalemia; medical expert; potassium blood level; disease surveillance; sodium restriction; healthy diet; Liraglutide; glucagon like peptide 1 receptor agonist; Estimated glomerular filtration rate; nephrologist; finerenone; dapagliflozin; mineralocorticoid antagonist; Empagliflozin; Canagliflozin; semaglutide; standard of care; Sodium glucose cotransporter 2 inhibitor; body weight management}, year = {2024}, eissn = {1935-5548}, pages = {S219-S230} } @article{MTMT:34766673, title = {Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program}, url = {https://m2.mtmt.hu/api/publication/34766673}, author = {Andersen, C.F. and Larsen, J.H. and Jensen, J. and Omar, M. and Nouhravesh, N. and Kistorp, C. and Tuxen, C. and Gustafsson, F. and Knop, F.K. and Forman, J.L. and Davidovski, F.S. and Jensen, L.T. and Højlund, K. and Køber, L. and Antonsen, L. and Poulsen, M.K. and Schou, M. and Møller, J.E.}, doi = {10.1016/j.ahj.2024.02.005}, journal-iso = {AM HEART J}, journal = {AMERICAN HEART JOURNAL}, volume = {271}, unique-id = {34766673}, issn = {0002-8703}, abstract = {Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have previously demonstrated cardioprotective properties in patients with type 2 diabetes, suggesting a preventive effect on heart failure (HF). The Empire Prevent trial program investigates the therapeutic potential for HF prevention by evaluating the cardiac, metabolic, and renal effects of the SGLT2 inhibitor empagliflozin in patients with increased risk of developing HF, but without diabetes or established HF. Methods: The Empire Prevent trial program is an investigator-initiated, double-blind, randomized clinical trial program including elderly and obese patients (60-84 years, body mass index >28 kg/m2) with at least one manifestation of hypertension, cardiovascular or chronic kidney disease, but no history of diabetes or HF. The aims are to investigate the effects of empagliflozin on 1) physical capacity and left ventricular and atrial structural changes with peak oxygen consumption and left ventricular mass as primary endpoints (Empire Prevent Cardiac), and 2) cardiac-adipose tissue interaction and volume homeostasis with primary endpoints of changes in epicardial adipose tissue and estimated extracellular volume (Empire Prevent Metabolic). At present, 138 of 204 patients have been randomized in the Empire Prevent trial program. Patients are randomized 1:1 to 180 days treatment with empagliflozin 10 mg daily or placebo, while undergoing a comprehensive examination program at baseline and follow-up. Discussion: The Empire Prevent trial program will mark the first step towards elucidating the potential of SGLT2 inhibition for HF prevention in an outpatient setting in elderly and obese patients with increased risk of developing HF, but with no history of diabetes or established HF. Furthermore, the Empire Prevent trial program will supplement the larger event-driven trials by providing mechanistic insights to the beneficial effects of SGLT2 inhibition. Trial Registration: Both parts of the trial program have been registered on September 13th 2021 (Clinical Trial Registration numbers: NCT05084235 and NCT05042973) before enrollment of the first patient. All patients will provide oral and written informed consent. The trial is approved by The Regional Committee on Health Research Ethics and the Danish Medicines Agency. Data will be disseminated through scientific meetings and peer-reviewed journals irrespective of outcome. © 2024 The Author(s)}, year = {2024}, eissn = {1097-6744}, pages = {84-96} } @article{MTMT:34799347, title = {Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction}, url = {https://m2.mtmt.hu/api/publication/34799347}, author = {Arbel, R. and Azab, A.N. and Oberoi, M. and Aboalhasan, E. and Star, A. and Elhaj, K. and Khalil, F. and Alnsasra, H.}, doi = {10.3389/fphar.2024.1357673}, journal-iso = {FRONT PHARMACOL}, journal = {FRONTIERS IN PHARMACOLOGY}, volume = {15}, unique-id = {34799347}, year = {2024}, eissn = {1663-9812} } @article{MTMT:34476864, title = {SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction}, url = {https://m2.mtmt.hu/api/publication/34476864}, author = {Avula, V. and Sharma, G. and Kosiborod, M.N. and Vaduganathan, M. and Neilan, T.G. and Lopez, T. and Dent, S. and Baldassarre, L. and Scherrer-Crosbie, M. and Barac, A. and Liu, J. and Deswal, A. and Khadke, S. and Yang, E.H. and Ky, B. and Lenihan, D. and Nohria, A. and Dani, S.S. and Ganatra, S.}, doi = {10.1016/j.jchf.2023.08.026}, journal-iso = {JACC HEART FAILURE}, journal = {JACC-HEART FAILURE}, volume = {12}, unique-id = {34476864}, issn = {2213-1779}, year = {2024}, eissn = {2213-1787}, pages = {67-78} } @article{MTMT:34477037, title = {Men are from mars, but women are not from venus: The benefits of SGLT2 inhibitors after myocardial infarction are independent of gender}, url = {https://m2.mtmt.hu/api/publication/34477037}, author = {Badimon, J. and Santos-Gallego, C.G.}, doi = {10.1016/j.hjc.2023.09.015}, journal-iso = {HELL J CARDIOL}, journal = {HELLENIC JOURNAL OF CARDIOLOGY}, volume = {75}, unique-id = {34477037}, issn = {1109-9666}, year = {2024}, eissn = {2241-5955}, pages = {93-95} } @article{MTMT:33419113, title = {Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit}, url = {https://m2.mtmt.hu/api/publication/33419113}, author = {Ballister, Briana and Hernandez, Rebecca L. and Quffa, Lieth H. and Franck, Andrew J.}, doi = {10.1177/08971900221144399}, journal-iso = {J PHARM PRACTICE}, journal = {JOURNAL OF PHARMACY PRACTICE}, volume = {37}, unique-id = {33419113}, issn = {0897-1900}, abstract = {Background Involvement of Clinical Pharmacy Specialists (CPS) in the care of patients with diabetes mellitus (DM) has been demonstrated to be beneficial. Whether this positive impact applies to increased use of cardiovascular risk-reducing medications is less well established. Objective To determine the association of CPS co-management on the prescription of diabetes medications with proven cardiovascular benefits for patients with DM and established cardiovascular disease in the primary care setting. Methods This retrospective cohort study evaluated patients in a Veterans Affairs health-system in primary care settings from February 1, 2019, through January 31, 2020. Patients were included if they had type 2 DM treated with at least one medication and had CVD. Patients were grouped into two cohorts for comparison, those with CPS co-management and those without. The primary outcome was the proportion of patients in each group with new prescriptions for empagliflozin or liraglutide initiated during the study timeframe. Results In total, 8058 patients were found eligible for inclusion in the study. Clinical co-management by a CPS was provided to 2099 patients. Study medications were prescribed, approved, and initiated in 596 patients during the study period, including 391 (18.6%) in the CPS group and 205 (3.4%) in the non-CPS group (P < .001). Conclusion This study showed CPS involvement is associated with increased prescribing of diabetes medications with proven cardiovascular benefits.}, keywords = {diabetes mellitus; cardiovascular disease; clinical pharmacy; clinical pharmacy specialists}, year = {2024}, eissn = {1531-1937}, pages = {435-441} } @article{MTMT:34536413, title = {GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis}, url = {https://m2.mtmt.hu/api/publication/34536413}, author = {Banerjee, M. and Pal, R. and Maisnam, I. and Mukhopadhyay, S.}, doi = {10.1016/j.dsx.2024.102943}, journal-iso = {DIABETES AND METABOLIC SYNDROME: CLINICAL RESEARCH AND REVIEWS}, journal = {DIABETES AND METABOLIC SYNDROME: CLINICAL RESEARCH AND REVIEWS}, volume = {18}, unique-id = {34536413}, issn = {1871-4021}, abstract = {Objective: Type-2 diabetes (T2D) poses a higher risk of noncardiovascular mortality in addition to the burden of cardiovascular mortality. The well-established cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) could solely explain their apparent effects on all-cause mortality in T2D. The present meta-analysis aims to pool their effects on noncardiovascular mortality in T2D and summarize the recent evidence on plausible pathways mediating these effects. Methods: PubMed, Embase, Web of Science, and clinical trial registries were searched for randomized controlled trials (RCTs) with ≥1-year duration in adults with T2D reporting both cardiovascular and all-cause mortality in treatment versus placebo arms (PROSPERO: CRD42022337559). Noncardiovascular mortality was calculated by subtracting cardiovascular mortality events from all-cause mortality and risk ratios (RRs) were calculated. Random-effects meta-analysis was done. GRADE framework was used to assess evidence quality. Results: We identified 17 eligible RCTs pooling data retrieved from 109,892 patients. Randomization to GLP-1 RA treatment versus placebo was associated with reduced noncardiovascular mortality (RR = 0.90; 95%CI: 0.81–0.99; I2 = 0 %; p < 0.05), consistent with their effects on cardiovascular mortality (RR = 0.88; 95%CI: 0.81–0.95; I2 = 0 %; p < 0.01) in T2D. Compared to placebo, SGLT2i significantly reduced noncardiovascular mortality (RR = 0.90; 95%CI: 0.82–0.99; I2 = 0 %; p < 0.05) along with cardiovascular mortality (RR = 0.84; 95%CI: 0.77–0.92; I2 = 28 %; p < 0.001). Subgroup analysis showed no significant effects of heart failure or renal function on treatment benefits of SGLT2i on noncardiovascular mortality (p value > 0.2 for subgroup differences). Conclusion: The impact of GLP-1RAs and SGLT2i on mortality in people with T2D extends beyond their cardiovascular benefits. © 2024}, keywords = {CANCER; DEMENTIA; DEPRESSION; Infections; liver disease; CKD; T2DM}, year = {2024} } @article{MTMT:34684418, title = {The effect of kidney function on guideline‐directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction}, url = {https://m2.mtmt.hu/api/publication/34684418}, author = {Bánfi‐Bacsárdi, Fanni and Pilecky, Dávid and Vámos, Máté and Majoros, Zsuzsanna and Török, Gábor Márton and Borsányi, Tünde Dóra and Dékány, Miklós and Solymossi, Balázs and Andréka, Péter and Duray, Gábor Zoltán and Kiss, Róbert Gábor and Nyolczas, Noémi and Muk, Balázs}, doi = {10.1002/clc.24244}, journal-iso = {CLIN CARDIOL}, journal = {CLINICAL CARDIOLOGY}, volume = {47}, unique-id = {34684418}, issn = {0160-9289}, year = {2024}, eissn = {1932-8737}, orcid-numbers = {Bánfi‐Bacsárdi, Fanni/0000-0002-5024-2820; Solymossi, Balázs/0000-0002-8652-706X; Duray, Gábor Zoltán/0000-0003-1286-6576; Kiss, Róbert Gábor/0000-0003-0514-7530; Muk, Balázs/0000-0003-0821-484X} } @article{MTMT:34434950, title = {Heart failure: update of the ESC 2023 guidelines}, url = {https://m2.mtmt.hu/api/publication/34434950}, author = {Bauersachs, J. and Soltani, S.}, doi = {10.1007/s00059-023-05221-2}, journal-iso = {HERZ}, journal = {HERZ}, volume = {49}, unique-id = {34434950}, issn = {0340-9937}, year = {2024}, eissn = {1615-6692}, pages = {19-21} } @article{MTMT:34749923, title = {Nonischemic or Dual Cardiomyopathy in Patients With Coronary Artery Disease}, url = {https://m2.mtmt.hu/api/publication/34749923}, author = {Bawaskar, P. and Thomas, N. and Ismail, K. and Guo, Y. and Chhikara, S. and Athwal, P.S.S. and Ranum, A. and Jadhav, A. and Mendez, A.H. and Nadkarni, I. and Frerichs, D. and Velangi, P. and Ergando, T. and Akram, H. and Kanda, A. and Shenoy, C.}, doi = {10.1161/CIRCULATIONAHA.123.067032}, journal-iso = {CIRCULATION}, journal = {CIRCULATION}, volume = {149}, unique-id = {34749923}, issn = {0009-7322}, year = {2024}, eissn = {1524-4539}, pages = {807-821} } @article{MTMT:34644991, title = {Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases}, url = {https://m2.mtmt.hu/api/publication/34644991}, author = {Berezin, Alexander E. and Berezina, Tetiana A.}, doi = {10.1177/03000605241227659}, journal-iso = {J INT MED RES}, journal = {JOURNAL OF INTERNATIONAL MEDICAL RESEARCH}, volume = {52}, unique-id = {34644991}, issn = {0300-0605}, keywords = {heart failure; kidney function; Renoprotection; circulating biomarkers; sodium-glucose cotransporter 2 inhibitors; chronic kidney diseases}, year = {2024}, eissn = {1473-2300} } @article{MTMT:34777746, title = {Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials}, url = {https://m2.mtmt.hu/api/publication/34777746}, author = {Bhatt, A.S. and Vaduganathan, M. and Claggett, B.L. and Kulac, I.J. and Anand, I.S. and Desai, A.S. and Fang, J.C. and Hernandez, A.F. and Jhund, P.S. and Kosiborod, M.N. and Sabatine, M.S. and Shah, S.J. and Vardeny, O. and McMurray, J.J.V. and Solomon, S.D. and Gaziano, T.A.}, doi = {10.1161/JAHA.123.032279}, journal-iso = {J AM HEART ASSOC}, journal = {JOURNAL OF THE AMERICAN HEART ASSOCIATION}, volume = {13}, unique-id = {34777746}, issn = {2047-9980}, year = {2024}, eissn = {2047-9980} } @article{MTMT:34742585, title = {Assessing trends and variability in outpatient dual testing for chronic kidney disease with urine albumin and serum creatinine, 2009-2018: A retrospective cohort study in the Veterans Health Administration System}, url = {https://m2.mtmt.hu/api/publication/34742585}, author = {Bhave, N.M. and Han, Y. and Steffick, D. and Bragg-Gresham, J. and Zivin, K. and Burrows, N.R. and Pavkov, M.E. and Tuot, D. and Powe, N.R. and Saran, R.}, doi = {10.1136/bmjopen-2023-073136}, journal-iso = {BMJ OPEN}, journal = {BMJ OPEN}, volume = {14}, unique-id = {34742585}, issn = {2044-6055}, abstract = {Background Simultaneous urine testing for albumin (UAlb) and serum creatinine (SCr), that is, 'dual testing,' is an accepted quality measure in the management of diabetes. As chronic kidney disease (CKD) is defined by both UAlb and SCr testing, this approach could be more widely adopted in kidney care. Objective We assessed time trends and facility-level variation in the performance of outpatient dual testing in the integrated Veterans Health Administration (VHA) system. Design, subjects and main measures This retrospective cohort study included patients with any inpatient or outpatient visit to the VHA system during the period 2009-2018. Dual testing was defined as UAlb and SCr testing in the outpatient setting within a calendar year. We assessed time trends in dual testing by demographics, comorbidities, high-risk (eg, diabetes) specialty care and facilities. A generalised linear mixed-effects model was applied to explore individual and facility-level predictors of receiving dual testing. Key results We analysed data from approximately 6.9 million veterans per year. Dual testing increased, on average, from 17.4% to 21.2%, but varied substantially among VHA centres (0.3%-43.7% in 2018). Dual testing was strongly associated with diabetes (OR 10.4, 95% CI 10.3 to 10.5, p<0.0001) and not associated with VHA centre complexity level. However, among patients with high-risk conditions including diabetes, <50% received dual testing in any given year. As compared with white veterans, black veterans were less likely to be tested after adjusting for other individual and facility characteristics (OR 0.93, 95% CI 0.92 to 0.93, p<0.0001). Conclusions Dual testing for CKD in high-risk specialties is increasing but remains low. This appears primarily due to low rates of testing for albuminuria. Promoting dual testing in high-risk patients will help to improve disease management and patient outcomes. © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.}, keywords = {Aged; Adult; Female; Middle Aged; Male; Humans; ARTICLE; human; diabetes mellitus; diabetes mellitus; diabetes mellitus; Retrospective Studies; Treatment Outcome; major clinical study; controlled study; cohort analysis; United States; United States; Comorbidity; Albuminuria; Outpatients; albumin; retrospective study; creatinine; creatinine; creatinine; chronic kidney failure; chronic kidney failure; creatinine blood level; blood sampling; Caucasian; high risk patient; kidney function; urinalysis; government; observational study; Veterans; general practice; outpatient; Primary Health Care; Primary Health Care; nephrology; health care management; Renal Insufficiency, Chronic; veteran; United States Department of Veterans Affairs; general medicine (see internal medicine); Veterans health; Veterans health; albumin urine level}, year = {2024}, eissn = {2044-6055} } @article{MTMT:34639437, title = {Latest pharmaceutical approaches across the spectrum of heart failure}, url = {https://m2.mtmt.hu/api/publication/34639437}, author = {Bismpos, Dimitrios and Wintrich, Jan and Hoevelmann, Julian and Boehm, Michael}, doi = {10.1007/s10741-024-10389-8}, journal-iso = {HEART FAIL REV}, journal = {HEART FAILURE REVIEWS}, volume = {29}, unique-id = {34639437}, issn = {1382-4147}, keywords = {heart failure; Heart failure with preserved ejection fraction (HFpEF); heart failure with reduced ejection fraction (hfref); Heart failure with mildly reduced ejection fraction (HFmrEF)}, year = {2024}, eissn = {1573-7322}, pages = {675-687} } @article{MTMT:34170056, title = {Sodium-glucose cotransporter-2 inhibition in a CKD patient with severe heart failure treated by high-dose diuretics and peritoneal ultrafiltration: lesson for the clinical nephrologist}, url = {https://m2.mtmt.hu/api/publication/34170056}, author = {Borrelli, S. and Garofalo, C. and Liberti, M.E. and Ruotolo, C. and Capozzi, F. and Yavorskiy, P. and De, Nicola L.}, doi = {10.1007/s40620-023-01766-x}, journal-iso = {J NEPHROL}, journal = {JOURNAL OF NEPHROLOGY}, volume = {37}, unique-id = {34170056}, issn = {1121-8428}, year = {2024}, eissn = {1724-6059}, pages = {199-201} } @article{MTMT:34766715, title = {Contemporary pharmacological treatment and management of heart failure}, url = {https://m2.mtmt.hu/api/publication/34766715}, author = {Bozkurt, B.}, doi = {10.1038/s41569-024-00997-0}, journal-iso = {NAT REV CARDIOL}, journal = {NATURE REVIEWS CARDIOLOGY}, volume = {In press}, unique-id = {34766715}, issn = {1759-5002}, abstract = {The prevention and treatment strategies for heart failure (HF) have evolved in the past two decades. The stages of HF have been redefined, with recognition of the pre-HF state, which encompasses asymptomatic patients who have developed either structural or functional cardiac abnormalities or have elevated plasma levels of natriuretic peptides or cardiac troponin. The first-line treatment of patients with HF with reduced ejection fraction includes foundational therapies with angiotensin receptor–neprilysin inhibitors, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, mineralocorticoid receptor antagonists, sodium–glucose cotransporter 2 (SGLT2) inhibitors and diuretics. The first-line treatment of patients with HF with mildly reduced ejection fraction or with HF with preserved ejection fraction includes SGLT2 inhibitors and diuretics. The timely initiation of these disease-modifying therapies and the optimization of treatment are crucial in all patients with HF. Reassessment after initiation of these therapies is recommended to evaluate patient symptoms, health status and left ventricular function, and timely referral to a HF specialist is necessary if a patient has persistent advanced HF symptoms or worsening HF. Lifestyle modification and treatment of comorbidities such as diabetes mellitus, ischaemic heart disease and atrial fibrillation are crucial through each stage of HF. This Review provides an overview of the management strategies for HF according to disease stages that are derived from the recommendations in the latest US and European HF guidelines. © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024.}, year = {2024}, eissn = {1759-5010}, pages = {In press} } @article{MTMT:34536404, title = {Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data}, url = {https://m2.mtmt.hu/api/publication/34536404}, author = {Brockmeyer, M. and Parco, C. and Vargas, K.G. and Westenfeld, R. and Jung, C. and Kelm, M. and Roden, M. and Akbulut, C. and Schlesinger, S. and Wolff, G. and Kuss, O.}, doi = {10.1007/s40620-023-01858-8}, journal-iso = {J NEPHROL}, journal = {JOURNAL OF NEPHROLOGY}, volume = {37}, unique-id = {34536404}, issn = {1121-8428}, abstract = {Background: Absolute treatment benefits—expressed as numbers needed to treat—of the glucose lowering and cardiovascular drugs, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose transporter 2 (SGLT2) inhibitors on renal outcomes remain uncertain. With the present meta-analysis of digitalized individual patient data, we aimed to display and compare numbers needed to treat of both drugs on a composite renal outcome. Methods: From Kaplan–Meier plots of major cardiovascular outcome trials of GLP-1 receptor agonists and SGLT2 inhibitors vs. placebo, we digitalized individual patient time-to-event information on composite renal outcomes with WebPlotDigitizer 4.2; numbers needed to treat from individual cardiovascular outcome trials were estimated using parametric Weibull regression models and compared to original data. Random-effects meta-analysis generated meta-numbers needed to treat with 95% confidence intervals (CI). Results: Twelve cardiovascular outcome trials (three for GLP-1 receptor agonists, nine for SGLT2 inhibitors) comprising 90,865 participants were included. Eight trials were conducted in primary type 2 diabetes populations, two in a primary heart failure and two in a primary chronic kidney disease population. Mean estimated glomerular filtration rate at baseline ranged between 37.3 and 85.3 ml/min/1.73 m2. Meta-analyses estimated meta-numbers needed to treat of 85 (95% CI 60; 145) for GLP-1 receptor agonists and 104 (95% CI 81; 147) for SGLT2 inhibitors for the composite renal outcome at the overall median follow-up time of 36 months. Conclusion: The present meta-analysis of digitalized individual patient data revealed moderate and similar absolute treatment benefits of GLP-1 receptor agonists and SGLT2 inhibitors compared to placebo for a composite renal outcome. Graphical Abstract: [Figure not available: see fulltext.] © 2024, The Author(s).}, keywords = {GLP-1 receptor agonist; SGLT2 inhibitor; Composite renal outcome; Absolute treatment effect}, year = {2024}, eissn = {1724-6059}, pages = {309-321} } @article{MTMT:34799296, title = {Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure}, url = {https://m2.mtmt.hu/api/publication/34799296}, author = {Burchill, L.J. and Jain, C.C. and Miranda, W.R.}, doi = {10.1016/j.jacc.2024.03.002}, journal-iso = {J AM COLL CARDIOL}, journal = {JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY}, volume = {83}, unique-id = {34799296}, issn = {0735-1097}, year = {2024}, eissn = {1558-3597}, pages = {1415-1417} } @article{MTMT:34668108, title = {2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)}, url = {https://m2.mtmt.hu/api/publication/34668108}, author = {Byrne, R.A. and Rossello, X. and Coughlan, J.J. and Barbato, E. and Berry, C. and Chieffo, A. and Claeys, M.J. and Dan, G.-A. and Dweck, M.R. and Galbraith, M. and Gilard, M. and Hinterbuchner, L. and Jankowska, E.A. and Jüni, P. and Kimura, T. and Kunadian, V. and Leosdottir, M. and Lorusso, R. and Pedretti, R.F.E. and Rigopoulos, A.G. and Gimenez, M.R. and Thiele, H. and Vranckx, P. and Wassmann, S. and Wenger, N.K. and Ibanez, B. and Halvorsen, S. and James, S. and Abdelhamid, M. and Aboyans, V. and Marsan, N.A. and Antoniou, S. and Asteggiano, R. and Bäck, M. and Capodanno, D. and Casado-Arroyo, R. and Cassese, S. and Čelutkiene, J. and Cikes, M. and Collet, J.-P. and Ducrocq, G. and Falk, V. and Fauchier, L. and Geisler, T. and Gorog, D.A. and Holmvang, L. and Jaarsma, T. and Jones, H.W. and Køber, L. and Koskinas, K.C. and Kotecha, D. and Krychtiuk, K.A. and Landmesser, U. and Lazaros, G. and Lewis, B.S. and Lindahl, B. and Linhart, A. and Løchen, M.-L. and Mamas, M.A. and McEvoy, J.W. and Mihaylova, B. and Mindham, R. and Mueller, C. and Neubeck, L. and Niebauer, J. and Nielsen, J.C. and Niessner, A. and Paradies, V. and Pasquet, A.A. and Petersen, S.E. and Prescott, E. and Rakisheva, A. and Rocca, B. and Rosano, G.M.C. and Sade, L.E. and Schiele, F. and Siller-Matula, J.M. and Sticherling, C. and Storey, R.F. and Thielmann, M. and Vrints, C. and Windecker, S. and Wiseth, R. and Witkowski, A. and ESC, Scientific Document Group}, doi = {10.1093/ehjacc/zuad107}, journal-iso = {EUR HEART J-ACUTE CA}, journal = {EUROPEAN HEART JOURNAL: ACUTE CARDIOVASCULAR CARE}, volume = {13}, unique-id = {34668108}, issn = {2048-8726}, keywords = {percutaneous coronary intervention; myocardial infarction; FIBRINOLYSIS; GUIDELINES; UNSTABLE ANGINA; acute coronary syndrome; Revascularization; secondary prevention; REPERFUSION THERAPY; RECOMMENDATIONS; antithrombotic therapy; INVASIVE STRATEGY; patient-centred care; ST-segment elevation myocardial infarction; Non-ST-elevation myocardial infarction; MINOCA; acute cardiac care; Highsensitivity troponin}, year = {2024}, eissn = {2048-8734}, pages = {55-161} } @article{MTMT:34600815, title = {Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients}, url = {https://m2.mtmt.hu/api/publication/34600815}, author = {Cai, Dabei and Chen, Qianwen and Mao, Lipeng and Xiao, Tingting and Wang, Yu and Gu, Qingqing and Wang, Qingjie and Ji, Yuan and Sun, Ling}, doi = {10.1007/s00228-024-03623-7}, journal-iso = {EUR J CLIN PHARMACOL}, journal = {EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY}, volume = {80}, unique-id = {34600815}, issn = {0031-6970}, abstract = {Objective: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented effects in reducing hospitalization or cardiovascular mortality, while the association of SGLT2 inhibitor dapagliflozin (DAPA) and the risk of acute kidney injury (AKI) in acute myocardial infarction (AMI) patients has not been comprehensively investigated. Therefore, we aimed to assess the association between DAPA and AKI risk in AMI patients after percutaneous coronary intervention (PCI) therapy. Methods: Using the Changzhou Acute Myocardial Infarction Registry database, we retrospectively included AMI patients from January 2017 to August 2021 and analyzed the risk of AKI and all-cause mortality after PCI therapy. The patients were divided into two groups according to the use of DAPA (DAPA group and Ctrl group). Patients in the DAPA group started to use DAPA after admission and continued its use during hospitalization and follow-up period. Baseline characteristics were balanced between the two groups with a propensity score matching (PSM) analysis. The outcome was AKI within 7 days after PCI and all-cause mortality during a follow-up of 2 years. Univariate and multivariate logistic regression analyses were used to assess the association between DAPA and AKI risk. Results: A total of 1839 AMI patients undergoing PCI were enrolled. DAPA was used in 278 (15.1%) patients. Postoperative AKI occurred in 351 (19.1%) cases. A 1:1 PSM analysis was used to reduce confounding factors. The multivariate stepwise regression analysis showed that DAPA (odds ratio, OR 0.66; 95% confidence interval, CI 0.44-0.97; P = 0.036) was an independent protective factor in the entire cohort. After matching, the use of DAPA in AMI patients was independently associated with a decline of AKI risk (OR 0.32; 95% CI, 0.19-0.53; P < 0.001) after hospital admission. Meanwhile, there were significant differences in mortality between the DAPA group and Ctrl group (2.5% vs. 7.6%, P = 0.012). Conclusion: SGLT2 inhibitor DAPA was associated with lower risks of incident AKI and all-cause mortality in AMI patients after PCI therapy.}, keywords = {MORTALITY; Acute myocardial infarction; acute kidney injury; dapagliflozin; Sodium-glucose cotransporter inhibitor}, year = {2024}, eissn = {1432-1041}, pages = {613-620} } @article{MTMT:34638158, title = {SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial?}, url = {https://m2.mtmt.hu/api/publication/34638158}, author = {Capodanno, Davide and Finocchiaro, Simone}, doi = {10.33963/v.phj.98860}, journal-iso = {KARDIOL POL}, journal = {KARDIOLOGIA POLSKA}, volume = {82}, unique-id = {34638158}, issn = {0022-9032}, year = {2024}, eissn = {1897-4279}, pages = {3-4} } @article{MTMT:34474391, title = {Effect of SGLT2 inhibitors on anemia and their possible clinical implications}, url = {https://m2.mtmt.hu/api/publication/34474391}, author = {Cases, A. and Cigarrán, S. and Górriz, J.L. and Nuñez, J.}, doi = {10.1016/j.nefro.2023.11.001}, journal-iso = {NEFROLOGIA}, journal = {NEFROLOGIA}, volume = {44}, unique-id = {34474391}, issn = {0211-6995}, abstract = {Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease. Since the first studies with these drugs, an initial increase in hemoglobin/hematocrit levels was observed, which was attributed to an increase in hemoconcentration associated with its diuretic effect, although it was soon seen that these drugs increased erythropoietin levels and erythropoiesis, and improved iron metabolism. Mediation studies found that the increase in hemoglobin was strongly associated with the cardiorenal benefits of these drugs. In this review, we discuss the mechanisms for improving erythropoiesis and the implication of the increase in hemoglobin on the cardiorenal prognostic benefit of these drugs. © 2023 Sociedad Española de Nefrología}, keywords = {ANEMIA; heart failure; Diabetes; chronic kidney disease; SGLT2 inhibitors}, year = {2024}, eissn = {1989-2284}, pages = {165-172} } @article{MTMT:33773542, title = {Impact of Inpatient Initiation of SGLT2 Inhibitors on Diuretic Requirements in Patients With Heart Failure}, url = {https://m2.mtmt.hu/api/publication/33773542}, author = {Cavagnini, Megan E. and Best, Emily E. and Skersick, Preston T. and Truitt, Kelsey P. and Musick, Kaitlin L. and Mangum, Blake R. and Hollis, Ian B. and Rodgers, Jo E.}, doi = {10.1177/08971900231159739}, journal-iso = {J PHARM PRACTICE}, journal = {JOURNAL OF PHARMACY PRACTICE}, volume = {37}, unique-id = {33773542}, issn = {0897-1900}, abstract = {Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve outcomes in patients with heart failure (HF) and are now included in guideline-directed medical therapy. Trials reporting the change in loop diuretic dose following SGLT2i initiation have indicated conflicting results. There is no clear guidance on whether reducing loop diuretic doses following SGLT2i initiation is appropriate. Objective: The purpose of this study is to assess the impact of SGLT2i initiation on diuretic adjustment in hospitalized patients with known or new HF. Methods: This was a retrospective, single health-system study assessing the change in loop diuretic dose in the 60 days following discharge for patients with HF initiated on SGLT2i therapy during a hospital admission or upon discharge. Secondary outcomes assessed effect on renal function and discontinuation of SGLT2i within the 60 day follow up period. Results: Forty percent of patients required loop diuretic dose adjustment, with 29% requiring a dose reduction within the 60 days following discharge. There was minimal change in serum creatinine or blood urea nitrogen. The SGLT2i was discontinued in 6 patients. Conclusions: After inpatient initiation of SGLT2is, approximately one-third of patients required a reduction in loop diuretic dose within 60 days following hospital discharge. Further study is recommended to confirm if empiric diuretic dose adjustments are appropriate in this HF population.}, keywords = {SGLT2 inhibitors; Empagliflozin; GDMT}, year = {2024}, eissn = {1531-1937}, pages = {683-689} } @article{MTMT:34638161, title = {Chronic Kidney Disease Associated with Ischemic Heart Disease: To What Extent Do Biomarkers Help?}, url = {https://m2.mtmt.hu/api/publication/34638161}, author = {Cepoi, Maria-Ruxandra and Duca, Stefania Teodora and Chetran, Adriana and Costache, Alexandru Dan and Spiridon, Marilena Renata and Afrasanie, Irina and Leanca, Sabina Andreea and Dmour, Bianca-Ana and Matei, Iulian Theodor and Miftode, Radu Stefan and Miftode, Larisa and Prepeliuc, Cristian Sorin and Haba, Mihai Stefan Cristian and Badescu, Minerva Codruta and Costache, Irina Iuliana}, doi = {10.3390/life14010034}, journal-iso = {LIFE-BASEL}, journal = {LIFE-BASEL}, volume = {14}, unique-id = {34638161}, keywords = {Inflammation; Biomarkers; chronic kidney disease; coronary artery disease; acute coronary syndrome}, year = {2024}, eissn = {2075-1729}, orcid-numbers = {Badescu, Minerva Codruta/0000-0001-8942-1909} } @article{MTMT:34747983, title = {Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance}, url = {https://m2.mtmt.hu/api/publication/34747983}, author = {Cersosimo, A. and Salerno, N. and Sabatino, J. and Scatteia, A. and Bisaccia, G. and De, Rosa S. and Dellegrottaglie, S. and Bucciarelli-Ducci, C. and Torella, D. and Leo, I.}, doi = {10.1186/s12933-024-02181-7}, journal-iso = {CARDIOVASC DIABETOL}, journal = {CARDIOVASCULAR DIABETOLOGY}, volume = {23}, unique-id = {34747983}, issn = {1475-2840}, abstract = {Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on cardiovascular morbidity and mortality. Despite several mechanisms have been proposed, the exact pathophysiology behind these effects is not yet fully understood. Cardiovascular imaging is key for the evaluation of diabetic patients, with an established role from the identification of early subclinical changes to long-term follow up and prognostic assessment. Among the different imaging modalities, CMR may have a key-role being the gold standard for volumes and function assessment and having the unique ability to provide tissue characterization. Novel techniques are also implementing the possibility to evaluate cardiac metabolism through CMR and thereby further increasing the potential role of the modality in this context. Aim of this paper is to provide a comprehensive review of changes in CMR parameters and novel CMR techniques applied in both pre-clinical and clinical studies evaluating the effects of SGLT2i and GLP-1Ra, and their potential role in better understanding the underlying CV mechanisms of these drugs. © The Author(s) 2024.}, keywords = {Humans; review; human; clinical feature; nonhuman; nuclear magnetic resonance imaging; Magnetic Resonance Imaging; drug effect; Diagnostic Imaging; cardiovascular system; cardiovascular system; cardiovascular system; cardiovascular diseases; Diabetes Mellitus, Type 2; cardiovascular disease; Hypoglycemic Agents; antidiabetic agent; Magnetic Resonance Spectroscopy; heart hypertrophy; clinical assessment; heart muscle fibrosis; heart protection; Nuclear magnetic resonance spectroscopy; clinical evaluation; evidence based practice; non insulin dependent diabetes mellitus; non insulin dependent diabetes mellitus; diabetic cardiomyopathy; treatment duration; heart ventricle remodeling; Liraglutide; glucagon like peptide 1 receptor agonist; Heart failure with preserved ejection fraction; cardiovascular magnetic resonance; cardiovascular magnetic resonance; exendin 4; heart failure with reduced ejection fraction; myocardial ischemia reperfusion injury; dapagliflozin; Glucagon-like peptide-1 receptor; glucagon like peptide 1 receptor; Empagliflozin; SGLT2i; GLP-1RA; Canagliflozin; Sodium glucose cotransporter 2 inhibitor; sotagliflozin; cerebral ischemia reperfusion injury; Sodium-glucose transporter 2 inhibitors}, year = {2024}, eissn = {1475-2840} } @article{MTMT:34799343, title = {Digoxin is Not Related to Mortality in Patients with Heart Failure: Results from the SELFIE-TR Registry}, url = {https://m2.mtmt.hu/api/publication/34799343}, author = {Çetin, Güvenç R. and Güvenç, T.S. and Çağlar, M.E. and Al, Arfaj A.A. and Behrad, A. and Yılmaz, M.B.}, doi = {10.1007/s40256-024-00639-3}, journal-iso = {AM J CARDIOVASC DRUG}, journal = {AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS}, unique-id = {34799343}, issn = {1175-3277}, year = {2024}, eissn = {1179-187X} } @{MTMT:34795794, title = {Natriuretic peptide testing strategies in heart failure: A 2023 update}, url = {https://m2.mtmt.hu/api/publication/34795794}, author = {Chaikijurajai, T. and Rincon-Choles, H. and Tang, W.H.W.}, booktitle = {Advances in Clinical Chemistry}, doi = {10.1016/bs.acc.2023.11.005}, volume = {118}, unique-id = {34795794}, abstract = {Natriuretic peptides (NPs), including B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), have been recommended as standard biomarkers for diagnosing heart failure (HF), and one of the strongest risk predictors for mortality and HF hospitalization regardless of ejection fraction (EF) and etiology of HF. BNP is an active neurohormone opposing renin-angiotensin-aldosterone and sympathetic nervous system overactivated in HF, whereas NT-proBNP is an inactive prohormone released from cardiomyocytes in response to wall stress. Despite substantial advances in the development of guideline-directed medical therapy (GDMT) for HF with reduced EF, studies demonstrating direct benefits of NP-guided chronic HF therapy on mortality, HF hospitalization, and GDMT optimization have yielded conflicting results. However, accumulating evidence shows that achieving prespecified BNP or NT-proBNP target over time is significantly associated with favorable outcomes, suggesting that benefits of serially measured NPs may be limited to particular groups of HF patients, such as those with extreme levels of baseline BNP or NT-proBNP, which could represent severe phenotypes of HF associated with natriuretic peptide resistance or cardiorenal syndrome. Over the past decade, clinical utilization of BNP and NT-proBNP has been expanded, especially using serial NP measurements for guiding HF therapy, optimizing GDMT and identifying at-risk patients with HF phenotypes who may be minimally symptomatic or asymptomatic. © 2024}, keywords = {Humans; NATRIURETIC PEPTIDES; human; Prognosis; Prognosis; Biomarkers; hospitalization; hospitalization; biological marker; heart failure; heart failure; heart failure; BRAIN NATRIURETIC PEPTIDE; Peptide fragments; peptide fragment; Natriuretic Peptide, Brain; guideline-directed medical therapy}, year = {2024}, pages = {155-203} } @article{MTMT:34623869, title = {Renal outcomes after contrast exposure in patients with diabetes who use sodium-glucose cotransporter 2 inhibitors}, url = {https://m2.mtmt.hu/api/publication/34623869}, author = {Chen, Chih-Wei and Su, Fu-You and Wang, Ping-Ping and Chuang, Ming-Tsang and Lin, Yi-Cheng and Kao, Chih-Chin and Huang, Chun-Yao}, doi = {10.1093/postmj/qgad118}, journal-iso = {POSTGRAD MED J}, journal = {POSTGRADUATE MEDICAL JOURNAL}, volume = {100}, unique-id = {34623869}, issn = {0032-5473}, keywords = {diabetes mellitus; Renal Insufficiency; sodium-glucose cotransporter 2 inhibitor; CONTRAST-INDUCED NEPHROPATHY; contrast exposure}, year = {2024}, eissn = {1469-0756}, pages = {142-150}, orcid-numbers = {Chuang, Ming-Tsang/0000-0001-8945-3513; Lin, Yi-Cheng/0000-0002-3599-7758} } @article{MTMT:34799342, title = {Improvements of myocardial strain and work in diabetes patients with normal ejection fraction after empagliflozin treatment}, url = {https://m2.mtmt.hu/api/publication/34799342}, author = {Cheng, X. and Huang, P. and Liu, H. and Bi, X. and Gao, Y. and Lu, R. and Gao, Y. and Liu, Y. and Deng, Y.}, doi = {10.1111/jdi.14199}, journal-iso = {J DIABETES INVEST}, journal = {JOURNAL OF DIABETES INVESTIGATION}, unique-id = {34799342}, issn = {2040-1116}, year = {2024}, eissn = {2040-1124} } @article{MTMT:34502113, title = {Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis}, url = {https://m2.mtmt.hu/api/publication/34502113}, author = {Chen, J. and Jiang, C. and Guo, M. and Zeng, Y. and Jiang, Z. and Zhang, D. and Tu, M. and Tan, X. and Yan, P. and Xu, X.M. and Long, Y. and Xu, Y.}, doi = {10.1186/s12933-023-02042-9}, journal-iso = {CARDIOVASC DIABETOL}, journal = {CARDIOVASCULAR DIABETOLOGY}, volume = {23}, unique-id = {34502113}, issn = {1475-2840}, abstract = {Purpose: Numerous clinical studies have explored sodium–glucose cotransporter 2 inhibitor (SGLT2i) in patients with chronic heart failure (CHF), with or without type 2 diabetes mellitus (T2DM), and SGLT2i were proved to significantly reduce CHF hospitalization, cardiovascular death, cardiovascular mortality, all-cause mortality and myocardial infarction in patients with or without T2DM. However, only a limited few have investigated the effects of SGLT-2i on HF disease-specific health status and cardiac function. This meta-analysis aims to assess the effects of SGLT2i on disease-specific health status and cardiac function in CHF patients. Methods: A comprehensive search was conducted of trials by searching in PubMed, EMBASE, CENTRAL, Scopus, and Web of Science, and two Chinese databases (CNKI and Wanfang), Clinical Trials (http://www.clinicaltrials.gov) were also searched. Results: A total of 18 randomized controlled trials (RCTs) involving 23,953 participants were included in the meta-analysis. The effects of SGLT2 inhibitors were compared with control or placebo groups in CHF with or without T2DM. The SGLT2 inhibitors group exhibited a significant reduction in pro b-type natriuretic peptide (NT-proBNP) levels by 136.03 pg/ml (95% confidence interval [CI]: −253.36, − 18.70; P = 0.02). Additionally, a greater proportion of patients in the SGLT2 inhibitors group showed a ≥ 20% decrease in NT-proBNP (RR = 1.45, 95% CI [0.92, 2.29], p = 0.072). However, no statistically significant difference was observed for the effects on B-type natriuretic peptide (BNP). The use of SGLT-2 inhibitors led to a noteworthy improvement in LVEF by 2.79% (95% CI [0.18, 5.39];P = 0.036). In terms of health status, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6-minute walk distance, SGLT2 inhibitors led to a significant improvement in KCCQ clinical summary (KCCQ-CS) score (WMD = 1.7, 95% CI [1.67, 1.73], P < 0.00001), KCCQ overall summary (KCCQ-OS) score (WMD = 1.73, 95% CI [0.94, 2.52], P < 0.00001), and KCCQ total symptom (KCCQ-TS) score (WMD = 2.88, 95% CI [1.7, 4.06], P < 0.00001). Furthermore, the occurrence of KCCQ-CS and KCCQ-OS score increases ≥ 5 points had relative risks (RR) of 1.25 (95% CI [1.11, 1.42], P < 0.00001) and 1.15 (95% CI [1.09, 1.22], P < 0.00001), respectively. Overall, SGLT2 inhibitors increased the 6-minute walk distance by 23.98 m (95% CI [8.34, 39.62]; P = 0.003) compared to control/placebo from baseline. Conclusions: The SGLT2 inhibitors treatment offers an effective strategy for improving NT-proBNP levels, Kansas City Cardiomyopathy Questionnaire scores and 6-minute walk distance in CHF with or without T2DM. These findings indicate that SGLT2i improve cardiac function and health status in CHF with or without T2DM, and provide valuable guidance for clinicians making treatment decisions for patients with CHF. © 2023, The Author(s).}, keywords = {Humans; ARTICLE; human; Chronic Disease; Chronic Disease; Randomized Controlled Trials as Topic; CARDIOMYOPATHY; drug effect; Health Status; Health Status; Health Status; Health Status; Comorbidity; Meta-analysis; heart failure; heart failure; heart failure; Diabetes Mellitus, Type 2; protein blood level; placebo; drug efficacy; heart function; BRAIN NATRIURETIC PEPTIDE; cardiomyopathies; systematic review; meta analysis; non insulin dependent diabetes mellitus; non insulin dependent diabetes mellitus; medical decision making; Natriuretic Peptide, Brain; randomized controlled trial (topic); cardiac patient; Chronic heart failure; Cardiac function; amino terminal pro brain natriuretic peptide; six minute walk test; SGLT2 inhibitors; Sodium glucose cotransporter 2 inhibitor; Sodium glucose cotransporter 2 inhibitor; heart left ventricle ejection time; Sodium-glucose transporter 2 inhibitors; Kansas City Cardiomyopathy Questionnaire}, year = {2024}, eissn = {1475-2840} } @article{MTMT:34766718, title = {Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement}, url = {https://m2.mtmt.hu/api/publication/34766718}, author = {Chioncel, O. and Čelutkienė, J. and Bělohlávek, J. and Kamzola, G. and Lainscak, M. and Merkely, Béla Péter and Miličić, D. and Nessler, J. and Ristić, A.D. and Sawiełajc, L. and Uchmanowicz, I. and Uuetoa, T. and Turgonyi, E. and Yotov, Y. and Ponikowski, P.}, doi = {10.1002/ehf2.14687}, journal-iso = {ESC HEART FAIL}, journal = {ESC HEART FAILURE}, unique-id = {34766718}, issn = {2055-5822}, abstract = {Despite improvements over recent years, morbidity and mortality associated with heart failure (HF) are higher in countries in the Central and Eastern Europe and Baltic region than in Western Europe. With the goal of improving the standard of HF care and patient outcomes in the Central and Eastern Europe and Baltic region, this review aimed to identify the main barriers to optimal HF care and potential areas for improvement. This information was used to suggest methods to improve HF management and decrease the burden of HF in the region that can be implemented at the national and regional levels. We performed a literature search to collect information about HF epidemiology in 11 countries in the region (Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, and Slovenia). The prevalence of HF in the region was 1.6–4.7%, and incidence was 3.1–6.0 per 1000 person-years. Owing to the scarcity of published data on HF management in these countries, we also collected insights on local HF care and management practices via two surveys of 11 HF experts representing the 11 countries. Based on the combined results of the literature review and surveys, we created national HF care and management profiles for each country and developed a common patient pathway for HF for the region. We identified five main barriers to optimal HF care: (i) lack of epidemiological data, (ii) low awareness of HF, (iii) lack of national HF strategies, (iv) infrastructure and system gaps, and (v) poor access to novel HF treatments. To overcome these barriers, we propose the following routes to improvement: (i) establish regional and national prospective HF registries for the systematic collection of epidemiological data; (ii) establish education campaigns for the public, patients, caregivers, and healthcare professionals; (iii) establish formal HF strategies to set clear and measurable policy goals and support budget planning; (iv) improve access to quality-of-care centres, multidisciplinary care teams, diagnostic tests, and telemedicine/telemonitoring; and (v) establish national treatment monitoring programmes to develop policies that ensure that adequate proportions of healthcare budgets are reserved for novel therapies. These routes to improvement represent a first step towards improving outcomes in patients with HF in the Central and Eastern Europe and Baltic region by decreasing disparities in HF care within the region and between the region and Western Europe. © 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.}, keywords = {Registries; Multidisciplinary care; Patient pathway; heart failure management; Central and Eastern Europe and Baltic region; Heart failure nursing}, year = {2024}, eissn = {2055-5822}, orcid-numbers = {Merkely, Béla Péter/0000-0001-6514-0723} } @article{MTMT:34694303, title = {The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction – A systematic review}, url = {https://m2.mtmt.hu/api/publication/34694303}, author = {Chong, J.H. and Chang, W.-T. and Chan, J.J. and Tan, T.J.Y. and Chan, J.W.K. and Wong, M. and Wong, F.Y. and Chuah, C.T.H.}, doi = {10.1016/j.cpcardiol.2024.102372}, journal-iso = {CURR PROB CARDIOLOGY}, journal = {CURRENT PROBLEMS IN CARDIOLOGY}, volume = {49}, unique-id = {34694303}, issn = {0146-2806}, abstract = {Background: Sodium–glucose cotransporter 2-inhibitors (SGLT2i) improve cardiovascular outcomes including reduction in risk of first hospitalisation for heart failure (HF), worsening HF and cardiovascular death regardless of HF or diabetes mellitus (DM) status. It is not known whether SGLT2i can prevent the development of incident HF or reduce the risk of HF in patients receiving trastuzumab with or without other concurrent anti-HER2 agent or sequential anthracycline for treatment of HER2 positive breast cancer. Patients with active malignancy or recent history of malignancy were excluded from participating in the main cardiovascular outcome trials involving SGLT2i. Aim: A systematic review was performed to objectively assess published literature on the cardioprotective effects of SGLT2i in breast cancer treatment-related cardiotoxicity. Methods: Systematic searches of Embase, Medline, The Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov databases were performed. Titles and abstracts were screened separately by two cardio-oncologists (JHC, WTC). Full texts of potentially eligible records were then assessed separately by JHC and WTC before inclusion into review upon joint agreement. Results: 479 records were identified from 3 databases (MEDLINE=51, EMBASE=408, CENTRAL=13) and 1 registry (Clinicaltrials.gov=7). 460 records were excluded based on title and abstract (including duplicates). 19 full text reports were assessed for eligibility and included in review (basic science/animal study paper 2, Clinicaltrials.gov randomised controlled trial submission 1 (currently recruiting), basic science/animal study conference abstract 5, case report 2, review 3, editorial comment 2, clinical guidelines 1, retrospective/registry-based conference abstract 3). Conclusion: Cardiotoxicity is the most common dose-limiting toxicity associated with trastuzumab. Discontinuation of trastuzumab however, can lead to worse cancer outcomes. There have been case reports, registry-based, retrospective cohort-based and mechanistic studies suggesting the cardioprotective potential of SGLT2i in cancer therapy-related cardiac dysfunction (CTRCD). Based on these, there is now a call for randomised controlled trials to be performed in this patient cohort to advise guideline-directed therapy for CTRCD, which will in turn also provide detailed safety information and improve cancer and cardiovascular outcomes. © 2024}, year = {2024}, eissn = {1535-6280} } @article{MTMT:34502121, title = {Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies}, url = {https://m2.mtmt.hu/api/publication/34502121}, author = {Chong, K. and Chang, J.K.-J. and Chuang, L.-M.}, doi = {10.1002/kjm2.12800}, journal-iso = {KAOHSIUNG J MED SCI}, journal = {KAOHSIUNG JOURNAL OF MEDICAL SCIENCES}, volume = {40}, unique-id = {34502121}, issn = {1607-551X}, abstract = {Several recent advances provide multiple health benefits to individuals with type 2 diabetes mellitus (T2DM). Pharmacological therapy is governed by person-centered factors, including comorbidities and treatment goals. Adults with T2DM who have an established/high risk of atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, require a treatment regimen that includes agents that are proven to reduce cardiorenal risk. Weight management plays a key role in reducing glucose for patients with T2DM. A glucose-reduction treatment regimen must consider weight management. Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure, cardiovascular and renal events. Glucagon-like peptide-1 (GLP-1) receptor agonists allow better control of glycemia, promote weight loss and reduce the risk of cardiovascular events. Newer Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 dual agonist, which activate GIP and GLP-1 receptors improve glycemic control and promote greater weight loss than GLP-1 receptor agonists. Several novel drugs are in the clinical development phase. This review pertains to recent advances in pharmacological management of type 2 diabetes. © 2024 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.}, keywords = {tirzepatide; glucagon-like peptide-1 (GLP-1) receptor agonists; insulin icodec; retatrutide; sodium glucose co-transporters 2 (SGLT2) inhibitors}, year = {2024}, eissn = {2410-8650}, pages = {212-220} } @article{MTMT:34742642, title = {Current Place of SGLT2i in the Management of Heart Failure: An Expert Opinion from India}, url = {https://m2.mtmt.hu/api/publication/34742642}, author = {Chopra, H.K. and Nair, T. and Wander, G.S. and Ponde, C.K. and Ray, S. and Khullar, D. and Nanda, N.C. and Narula, J. and Kasliwal, R.R. and Rana, D.S. and Kirpalani, A. and Sawhney, J.P.S. and Chandra, P. and Mehta, Y. and Kumar, V. and Tewari, S. and Pancholia, A.K. and Kher, V. and Bansal, S. and Mittal, S. and Kerkar, P. and Sahoo, P.K. and Hotchandani, R. and Prakash, S. and Chauhan, N. and Rastogi, V. and Jabir, A. and Shanmugasundaram, S. and Tiwaskar, M. and Sinha, A. and Gupta, V. and Mishra, S.S. and Routray, S.N. and Omar, A.K. and Swami, O.C. and Jaswal, A. and Alam, S. and Passey, R. and Rajput, R. and Paul, J. and Kapoor, A. and Prabhakar, D. and Chandra, S. and Malhotra, P. and Singh, V.P. and Bansal, M. and Shah, P. and Jain, S. and Bhargava, M. and Vijayalakshmi, I.B. and Varghaese, K. and Jain, D. and Goel, A. and Mehmood, K. and Gaur, N. and Tandon, R. and Moorthy, A. and George, S. and Katyal, V.K. and Mantri, R.R. and Mehrotra, R. and Bhalla, D. and Mittal, V. and Rao, S. and Jagia, M. and Singh, H. and Awasthi, S. and Sattur, A. and Mishra, R. and Pandey, A. and Chawla, R. and Jaggi, S. and Sehgal, B. and Sehgal, A. and Goel, N. and Gupta, R. and Kubba, S. and Chhabra, A. and Bagga, S. and Shastry, N.R.}, doi = {10.59556/japi.71.0440}, journal-iso = {J ASSOC PHYS INDIA}, journal = {JOURNAL OF ASSOCIATION OF PHYSICIANS OF INDIA}, volume = {72}, unique-id = {34742642}, issn = {0004-5772}, abstract = {Heart failure (HF) is a global health concern that is prevalent in India as well. HF is reported at a younger age in Indian patients with comorbidity of type 2 diabetes (T2DM) in approximately 50% of patients. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), originally approved for T2DM, are new guideline-recommended and approved treatment strategies for HF. Extensive evidence highlights that SGLT2i exhibits profound cardiovascular (CV) benefits beyond glycemic control. SGLT2i, in conjunction with other guideline-directed medical therapies (GMDT), has additive effects in improving heart function and reducing adverse HF outcomes. The benefits of SGLT2i are across a spectrum of patients, with and without diabetes, suggesting their potential place in broader HF populations irrespective of ejection fraction (EF). This consensus builds on the updated evidence of the efficacy and safety of SGLT2i in HF and recommends its place in therapy with a focus on Indian patients with HF. ©The Author(s). 2024.}, year = {2024}, pages = {63-73} } @article{MTMT:34742629, title = {Heart failure is a systemic disease}, url = {https://m2.mtmt.hu/api/publication/34742629}, author = {Christa, M. and Maack, C.}, doi = {10.1007/s12181-024-00677-w}, journal-iso = {KARDIOLOGIE}, journal = {KARDIOLOGIE}, volume = {18}, unique-id = {34742629}, issn = {2731-7129}, abstract = {Heart failure affects approximately 4% of the German population, is the most common reason for hospitalization and is associated with a high morbidity and mortality. The prevalence increases with age, and older patients also frequently have diseases of other organ systems, such as chronic kidney disease, anemia, obesity, and type 2 diabetes mellitus. The number of comorbidities has a significant impact on the prognosis. Therefore, heart failure is no longer regarded as an isolated organ disease but as a systemic disease in which the heart is in communication with other organs. This communication is governed in particular through neuroendocrine activation, inflammation and metabolism. While previous treatments mainly focused on the neuroendocrine activation, more recent approaches target metabolism and inflammation. Depending on the approach, the clinical results of these interventions show that not only the heart, but also the kidneys, metabolic and possibly also tumor diseases can be favorably influenced. This illustrates that the treatment of heart failure is an interdisciplinary approach, in which cardiologists should work closely with other disciplines of internal medicine. The present review focuses on the cardiorenal metabolic system in patients with heart failure, and how therapeutic interventions targeting this system impact the generation and course heart failure. © Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e.V. Published by Springer Medizin Verlag GmbH, ein Teil von Springer Nature - all rights reserved 2024.}, keywords = {OBESITY; heart failure; Diabetes; chronic kidney disease; comorbidities}, year = {2024}, eissn = {2731-7137}, pages = {135-142} } @article{MTMT:34777770, title = {Metabolic Rewiring and Communication: An Integrative View of Kidney Proximal Tubule Function}, url = {https://m2.mtmt.hu/api/publication/34777770}, author = {Chrysopoulou, M. and Rinschen, M.M.}, doi = {10.1146/annurev-physiol-042222-024724}, journal-iso = {ANNU REV PHYSIOL}, journal = {ANNUAL REVIEW OF PHYSIOLOGY}, volume = {86}, unique-id = {34777770}, issn = {0066-4278}, year = {2024}, eissn = {1545-1585}, pages = {405-427} } @article{MTMT:34740411, title = {Sex-related similarities and differences in responses to heart failure therapies}, url = {https://m2.mtmt.hu/api/publication/34740411}, author = {Chyou, J.Y. and Qin, H. and Butler, J. and Voors, A.A. and Lam, C.S.P.}, doi = {10.1038/s41569-024-00996-1}, journal-iso = {NAT REV CARDIOL}, journal = {NATURE REVIEWS CARDIOLOGY}, volume = {In press}, unique-id = {34740411}, issn = {1759-5002}, abstract = {Although sex-related differences in the epidemiology, risk factors, clinical characteristics and outcomes of heart failure are well known, investigations in the past decade have shed light on an often overlooked aspect of heart failure: the influence of sex on treatment response. Sex-related differences in anatomy, physiology, pharmacokinetics, pharmacodynamics and psychosocial factors might influence the response to pharmacological agents, device therapy and cardiac rehabilitation in patients with heart failure. In this Review, we discuss the similarities between men and women in their response to heart failure therapies, as well as the sex-related differences in treatment benefits, dose–response relationships, and tolerability and safety of guideline-directed medical therapy, device therapy and cardiac rehabilitation. We provide insights into the unique challenges faced by men and women with heart failure, highlight potential avenues for tailored therapeutic approaches and call for sex-specific evaluation of treatment efficacy and safety in future research. © Springer Nature Limited 2024.}, year = {2024}, eissn = {1759-5010} } @article{MTMT:34742604, title = {Current experimental and early investigational agents for cardiac fibrosis: where are we at?}, url = {https://m2.mtmt.hu/api/publication/34742604}, author = {Ciampi, C.M. and Sultana, A. and Ossola, P. and Farina, A. and Fragasso, G. and Spoladore, R.}, doi = {10.1080/13543784.2024.2326024}, journal-iso = {EXPERT OPIN INV DRUG}, journal = {EXPERT OPINION ON INVESTIGATIONAL DRUGS}, volume = {33}, unique-id = {34742604}, issn = {1354-3784}, abstract = {Introduction: Myocardial fibrosis (MF) is induced by factors activating pro-fibrotic pathways such as acute and prolonged inflammation, myocardial ischemic events, hypertension, aging process, and genetically-linked cardiomyopathies. Dynamics and characteristics of myocardial fibrosis development are very different. The broad range of myocardial fibrosis presentations suggests the presence of multiple potential targets. Area covered: Heart failure treatment involves medications primarily aimed at counteracting neurohormonal activation. While these drugs have demonstrated efficacy against MF, not all specifically target inflammation or fibrosis progression with some exceptions such as RAAS inhibitors. Consequently, new therapies are being developed to address this issue. This article is aimed to describe anti-fibrotic drugs currently employed in clinical practice and emerging agents that target specific pathways, supported by evidence from both preclinical and clinical studies. Expert opinion: Despite various preclinical findings suggesting the potential utility of new drugs and molecules for treating cardiac fibrosis in animal models, there is a notable scarcity of clinical trials investigating these effects. However, the pathology of damage and repair in the heart muscle involves a complex network of interconnected inflammatory pathways and various types of immune cells. Our comprehension of the positive and negative roles played by specific immune cells and cytokines is an emerging area of research. © 2024 Informa UK Limited, trading as Taylor & Francis Group.}, keywords = {emerging therapies; Heart failure treatment; reverse remodeling; neurohormonal activation; Anti-fibrotic drugs; Myocardial fibrosis (MF); pro-fibrotic pathways}, year = {2024}, eissn = {1744-7658}, pages = {389-404} } @article{MTMT:34799293, title = {Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes}, url = {https://m2.mtmt.hu/api/publication/34799293}, author = {Ciardullo, S. and Savaré, L. and Rea, F. and Perseghin, G. and Corrao, G.}, doi = {10.1002/dmrr.3791}, journal-iso = {DIABETES-METAB RES}, journal = {DIABETES-METABOLISM RESEARCH AND REVIEWS}, volume = {40}, unique-id = {34799293}, issn = {1520-7552}, year = {2024}, eissn = {1520-7560} } @article{MTMT:34750144, title = {Efficacy of Guideline-Directed Medical Therapy in Heart Failure Patients With and Without Chronic Kidney Disease: A Meta-Analysis of 63,677 Patients}, url = {https://m2.mtmt.hu/api/publication/34750144}, author = {Clark, K.M. and Mahboob, F. and Evans, J. and Sun, J.H. and Wang, N.}, doi = {10.1016/j.hlc.2023.12.013}, journal-iso = {HEART LUNG CIRC}, journal = {HEART LUNG AND CIRCULATION}, volume = {33}, unique-id = {34750144}, issn = {1443-9506}, abstract = {Background: Chronic kidney disease (CKD) coexists in up to 50% of heart failure (HF) patients, affecting both those with reduced ejection fraction (HFrEF) and those with preserved ejection fraction (HFpEF). Although the efficacy of several guideline-directed medical therapies (GDMT) has been well established, the treatment recommendations are similar for those patients with HF with and without CKD. We aimed to investigate the efficacy of GDMT in patients with HF with versus those without CKD. Method: This systematic review and meta-analysis included randomised controlled trials that compared the efficacy of GDMT (angiotensin-converting enzyme inhibitor [ACE-I], beta blocker, sodium-glucose cotransporter-2 inhibitor, mineralocorticoid receptor antagonist, angiotensin receptor-neprilysin inhibitor) in patients with HF with and without CKD. The primary outcome was the composite of cardiovascular death and HF hospitalisation. Risk ratios (RR) were pooled using random-effects meta-analysis. Results: A total of 19 trials (15 trials in HFrEF and four trials in HFpEF) enrolling 63,677 (38% had CKD) participants were included. Among HFrEF patients, GDMT reduced the primary endpoint in those with CKD (RR 0.77, 95% confidence interval [CI] 0.72-0.82) and without CKD (RR 0.79, 95% CI 0.74–0.84). Among HFpEF patients, the pooled summary RR for GDMT reducing the primary endpoint was 0.82 (95% CI 0.74-0.91) among those with CKD and 0.88 (95% CI 0.77-0.99) among those without CKD. There was no significant difference in the efficacy of GDMT in head-to-head comparisons between those with and without CKD in HFrEF (ratio of RR 0.97, 95% CI 0.88-1.06) and HFpEF (ratio of RR 0.94, 95% CI 0.80-1.11). Conclusions: Among patients with HF, GDMT had a consistent effect in reducing adverse cardiovascular events in those with and without CKD. Future studies should investigate the best strategy to ensure patients with HF with CKD receive and tolerate GDMT when indicated. © 2024 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ)}, keywords = {clinical trial; Meta-analysis; heart failure; chronic kidney disease}, year = {2024}, eissn = {1444-2892}, pages = {281-291} } @article{MTMT:34502124, title = {Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia}, url = {https://m2.mtmt.hu/api/publication/34502124}, author = {Cohen, B. and Harris, Y.T. and Schulman-Rosenbaum, R.}, doi = {10.1016/j.eprac.2023.11.014}, journal-iso = {ENDOCR PRACT}, journal = {ENDOCRINE PRACTICE}, volume = {30}, unique-id = {34502124}, issn = {1530-891X}, abstract = {Objective: Hyperglycemia in patients with type 2 diabetes mellitus is frequently encountered in the hospital setting. The recent guidelines for the management of inpatient hyperglycemia have included the use of dipeptidyl peptidase 4 inhibitors as an alternative to standard insulin therapy in select patients. This raises the question of the inpatient use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), which have gained increasing popularity in the outpatient setting because of beneficial cardiovascular and renal outcomes. This article describes the risks associated with the use of SGLT2i for the management of inpatient hyperglycemia. Methods: A literature review was performed using PubMed and Google Scholar for studies assessing the inpatient use of SGLT2i. Search terms included “SGLT2 inhibitors,” “euglycemic DKA,” “inpatient hyperglycemia,” “DPP4 inhibitors,” “hypovolemia,” and “urinary tract infections.” Studies not written in English were excluded. Forty-eight articles were included. Results: Review of the literature showed significant safety concerns with the use of SGLT2i for the inpatient management of hyperglycemia. Hospitalized patients treated with SGLT2i were at increased risk of diabetic ketoacidosis, euglycemic diabetic ketoacidosis, hypovolemia, and urinary tract infections. When compared head-to-head, SGLT2i were not more effective for inpatient glycemic control than dipeptidyl peptidase 4 inhibitors and did not reduce insulin requirements when used in combination with insulin. Although SGLT2i can be considered for the treatment of congestive heart failure, they should be started close to or at the time of discharge. Conclusion: Although SGLT2i are a preferred pharmacotherapy class for the outpatient management of type 2 diabetes mellitus, there are considerable safety concerns when using them in a hospital setting, and avoidance is recommended. © 2023 AACE}, keywords = {hyperglycemia; type 2 diabetes mellitus; diabetic ketoacidosis; SGLT2 inhibitor; Euglycemic DKA; Inpatient diabetes}, year = {2024}, eissn = {1934-2403}, pages = {402-408} } @article{MTMT:34123049, title = {A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes}, url = {https://m2.mtmt.hu/api/publication/34123049}, author = {Cowart, Kevin and Coon, Scott and Carris, Nicholas W. W.}, doi = {10.1177/10600280231190443}, journal-iso = {ANN PHARMACOTHER}, journal = {ANNALS OF PHARMACOTHERAPY}, volume = {58}, unique-id = {34123049}, issn = {1060-0280}, abstract = {Objective: To review the pharmacology of bexagliflozin in addition to its safety and efficacy from available clinical trials used for its approval, as well as available clinical evidence to date. Data Sources: A search of the National Institutes of Health Clinical Trials Registry (http://www.clinicaltrials.gov) and PubMed database was performed from inception through June 1, 2023. Study Selection and Data Extraction Quantification: The following study designs were included: metaanalyses, systematic review, clinical trial, or observational study design. Abstracts and drug monographs were also reviewed. Narrative or scoping reviews were excluded. Only articles in the English language and those evaluating the pharmacology, pharmacokinetics, safety, or efficacy of bexaglifozin in humans were included. Data Synthesis: Bexagliflozin reduces hemoglobin A1c similar to 0.5% with similar reductions in systolic blood pressure and body weight to other SGLT2 inhibitors. No cardiovascular outcomes trial is published, nor ongoing at this time. Adverse effects are similar to other SGLT2 inhibitors (genital mycotic and urinary tract infections, increased urination) including a warning for lower extremity amputation similar to canagliflozin. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Although no cost-effectiveness data are available, statements from the manufacturer suggest a competitive price point. Given limited trial data, lower cost, if chosen, may create a temporary niche for bexagliflozin pending generic availability of other SGLT2 inhibitors. However, given lack of cardiovascular and renal outcome data, empagliflozin, dapagliflozin, or canagliflozin may be preferred. Conclusion: Bexagliflozin appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of T2D.}, keywords = {ENDOCRINOLOGY; Diabetes; family medicine; Type 2}, year = {2024}, eissn = {1542-6270}, pages = {514-522}, orcid-numbers = {Cowart, Kevin/0000-0002-6880-1600} } @article{MTMT:34536407, title = {Medicines optimization prior to discharge in patients admitted to hospital with heart failure}, url = {https://m2.mtmt.hu/api/publication/34536407}, author = {Cuthbert, J.J. and Brown, O.I. and Pellicori, P. and Dobbs, K. and Bulemfu, J. and Kazmi, S. and Sokoreli, I. and Pauws, S.C. and Riistama, J.M. and Cleland, J.G.F. and Clark, A.L.}, doi = {10.1002/ehf2.14638}, journal-iso = {ESC HEART FAIL}, journal = {ESC HEART FAILURE}, volume = {11}, unique-id = {34536407}, issn = {2055-5822}, abstract = {Aims: Approximately half of patients with heart failure and a reduced ejection fraction (HeFREF) are discharged from hospital on triple therapy [angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), beta-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs)]. We investigated what proportion of patients are on optimal doses prior to discharge and how many might be eligible for initiation of sacubitril–valsartan or sodium-glucose co-transporter-2 inhibitors (SGLT2Is). Methods and results: Between 2012 and 2017, 1277 patients admitted with suspected heart failure were enrolled at a single hospital serving a local community around Kingston upon Hull, UK. Eligibility for sacubitril–valsartan or SGLT2I was based on entry criteria for the PIONEER-HF, DAPA-HF, and EMPEROR-Reduced trials. Four hundred fifty-five patients had HeFREF with complete data on renal function, heart rate, and systolic blood pressure (SBP) prior to discharge. Eighty-three per cent of patients were taking an ACE-I or ARB, 85% a BB, and 63% an MRA at discharge. More than 60% of patients were eligible for sacubitril–valsartan and >70% for SGLT2I. Among those not already receiving a prescription, 37%, 28%, and 49% were eligible to start ACE-I or ARB, BB, and MRA, respectively. Low SBP (≤105 mmHg) was the most frequent explanation for failure to initiate or up-titrate therapy. Conclusions: Most patients admitted for heart failure are eligible for initiation of life-prolonging medications prior to discharge. A hospital admission may be a common missed opportunity to improve treatment for patients with HeFREF. © 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.}, keywords = {heart failure; DISCHARGE; inpatient; quadruple therapy; Medicine optimization}, year = {2024}, eissn = {2055-5822}, pages = {950-961} } @article{MTMT:34777796, title = {The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review}, url = {https://m2.mtmt.hu/api/publication/34777796}, author = {Dabour, M.S. and George, M.Y. and Daniel, M.R. and Blaes, A.H. and Zordoky, B.N.}, doi = {10.1016/j.jaccao.2024.01.007}, journal-iso = {JACC-CARDIOONCOL}, journal = {JACC. CARDIOONCOLOGY}, volume = {6}, unique-id = {34777796}, issn = {2666-0873}, year = {2024}, eissn = {2666-0873}, pages = {159-182} } @article{MTMT:34549777, title = {Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights}, url = {https://m2.mtmt.hu/api/publication/34549777}, author = {D’Amato, Andrea and Prosperi, Silvia and Severino, Paolo and Myftari, Vincenzo and Labbro Francia, Aurora and Cestiè, Claudia and Pierucci, Nicola and Marek-Iannucci, Stefanie and Mariani, Marco Valerio and Germanò, Rosanna and Fanisio, Francesca and Lavalle, Carlo and Maestrini, Viviana and Badagliacca, Roberto and Mancone, Massimo and Fedele, Francesco and Vizza, Carmine Dario}, doi = {10.3390/ijms25031574}, journal-iso = {INT J MOL SCI}, journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES}, volume = {25}, unique-id = {34549777}, issn = {1661-6596}, abstract = {Worsening heart failure (WHF) is a severe and dynamic condition characterized by significant clinical and hemodynamic deterioration. It is characterized by worsening HF signs, symptoms and biomarkers, despite the achievement of an optimized medical therapy. It remains a significant challenge in cardiology, as it evolves into advanced and end-stage HF. The hyperactivation of the neurohormonal, adrenergic and renin-angiotensin-aldosterone system are well known pathophysiological pathways involved in HF. Several drugs have been developed to inhibit the latter, resulting in an improvement in life expectancy. Nevertheless, patients are exposed to a residual risk of adverse events, and the exploration of new molecular pathways and therapeutic targets is required. This review explores the current landscape of WHF, highlighting the complexities and factors contributing to this critical condition. Most recent medical advances have introduced cutting-edge pharmacological agents, such as guanylate cyclase stimulators and myosin activators. Regarding device-based therapies, invasive pulmonary pressure measurement and cardiac contractility modulation have emerged as promising tools to increase the quality of life and reduce hospitalizations due to HF exacerbations. Recent innovations in terms of WHF management emphasize the need for a multifaceted and patient-centric approach to address the complex HF syndrome.}, keywords = {LEVOSIMENDAN; Omecamtiv mecarbil; vericiguat; Sodium-glucose cotransporter-2 inhibitors (SGLT2i); worsening heart failure; cardiac contractility modulation (CCM)}, year = {2024}, eissn = {1422-0067}, orcid-numbers = {Severino, Paolo/0000-0001-6211-4482; Pierucci, Nicola/0000-0002-5985-4081; Marek-Iannucci, Stefanie/0000-0001-9621-3198; Mariani, Marco Valerio/0000-0002-9480-1209; Fanisio, Francesca/0000-0002-1488-7015; Maestrini, Viviana/0000-0002-3225-8378; Badagliacca, Roberto/0000-0002-7887-5961; Mancone, Massimo/0000-0002-0881-7299; Vizza, Carmine Dario/0000-0002-3540-4983} } @article{MTMT:34607569, title = {Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target}, url = {https://m2.mtmt.hu/api/publication/34607569}, author = {Dattani, Abhishek and Singh, Anvesha and Mccann, Gerry P. and Gulsin, Gaurav S.}, doi = {10.3390/jcdd11010012}, journal-iso = {J CARDIOVASC DEV DIS}, journal = {JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE}, volume = {11}, unique-id = {34607569}, issn = {2308-3425}, abstract = {Type 2 diabetes (T2D) is a multisystem disease with rapidly increasing global prevalence. Heart failure has emerged as a major complication of T2D. Dysregulated myocardial calcium handling is evident in the failing heart and this may be a key driver of cardiomyopathy in T2D, but until recently this has only been demonstrated in animal models. In this review, we describe the physiological concepts behind calcium handling within the cardiomyocyte and the application of novel imaging techniques for the quantification of myocardial calcium uptake. We take an in-depth look at the evidence for the impairment of calcium handling in T2D using pre-clinical models as well as in vivo studies, following which we discuss potential novel therapeutic approaches targeting dysregulated myocardial calcium handling in T2D.}, keywords = {Diabetes; Calcium handling; manganese-enhanced MRI}, year = {2024}, eissn = {2308-3425} } @article{MTMT:34639873, title = {Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database}, url = {https://m2.mtmt.hu/api/publication/34639873}, author = {de Germay, Sibylle and Pambrun, Elodie and Pariente, Antoine and Grenet, Guillaume and Bezin, Julien and Faillie, Jean-Luc}, doi = {10.1111/dom.15472}, journal-iso = {DIABETES OBES METAB}, journal = {DIABETES OBESITY & METABOLISM}, volume = {26}, unique-id = {34639873}, issn = {1462-8902}, keywords = {Antidiabetic drug; Type 2 diabetes; Pharmacoepidemiology; sodium-glucose cotransporter-2 inhibitor}, year = {2024}, eissn = {1463-1326}, pages = {1678-1686}, orcid-numbers = {Grenet, Guillaume/0000-0002-5237-2581} } @article{MTMT:34799299, title = {Feasibility and Findings of Including Self-Identified Adult Congenital Heart Disease Patients in the INVESTED Trial}, url = {https://m2.mtmt.hu/api/publication/34799299}, author = {Dehghani, P. and Srivatsav, V. and Vardeny, O. and Grewal, J. and Opotowsky, A.R. and Muhll, I.V. and Keir, M. and Ducas, R. and Singh, J. and Kim, K. and Joseph, J. and Aboulhosn, J. and Havighurst, T. and Hegde, S.M. and Bhatt, D.L. and Solomon, S. and Farkouh, M. and Goodman, S.G. and Moe, T.G. and Udell, J.A.}, doi = {10.1016/j.jacadv.2024.100897}, journal-iso = {JACC: ADVANCES}, journal = {JACC: ADVANCES}, volume = {3}, unique-id = {34799299}, year = {2024}, eissn = {2772-963X} } @article{MTMT:34495176, title = {Moving Beyond Cardiotoxicity Detection to Prevention: A Pharmacologic Review}, url = {https://m2.mtmt.hu/api/publication/34495176}, author = {Dent, Susan and Rader, Ryan K. and White, Olivia and Patterson, Brandy and Moore, Heather N.}, doi = {10.1007/s11936-023-01030-2}, journal-iso = {CURR TREAT OPTIONS CARDIOVASC MED}, journal = {CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE}, volume = {26}, unique-id = {34495176}, issn = {1092-8464}, abstract = {Purpose of reviewCardio-oncology is a subspecialty of medicine focused on minimizing the risk of cardiovascular (CV) toxicity in patients receiving potentially cardiotoxic cancer therapy. While the literature has previously focused on detection of CV toxicity, there has been growing interest in primary prevention strategies for cancer therapy-related cardiovascular toxicity (CTR-CVT).Recent findingsSeveral trials have investigated the role of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and/or beta-blockers with mixed results, prompting researchers to assess alternatives, e.g., statins and sodium-glucose co-transporter-2 inhibitors (SGLT-2i). In this review, we discuss the positive and negative clinical trial results relating to these two drug classes. Ongoing prevention-focused clinical trials include ARBs in combination with neprilysin inhibitors (ARNis), azeliragon, and ivabradine. Further research is needed to discern the true benefit of novel agents and, importantly, the specific populations that would derive the most benefit.SummaryIn this review, we focus on results from recently reported studies exploring the potential benefit of pharmacologic approaches in primary prevention. There are currently no definitive signals strongly recommending a specific class of drugs for primary prevention in patients with cancer. Further research is required to determine which subset of patients might benefit from primary prevention strategies.}, keywords = {CARDIAC DYSFUNCTION; enalapril; Cardio-oncology; Prevention strategies}, year = {2024}, eissn = {1534-3189}, pages = {1-12} } @article{MTMT:34549392, title = {Heartfelt Breakthroughs: Elevating Quality of Life with Cutting-Edge Advances in Heart Failure Treatment}, url = {https://m2.mtmt.hu/api/publication/34549392}, author = {Devadoss, Ramprakash and Dhillon, Gagandeep and Sharma, Pranjal and Verma, Ram Kishun and Munjal, Ripudaman and Kashyap, Rahul}, doi = {10.3390/jcdd11010015}, journal-iso = {J CARDIOVASC DEV DIS}, journal = {JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE}, volume = {11}, unique-id = {34549392}, issn = {2308-3425}, abstract = {Heart failure is a cardiovascular condition, leading to fatigue, breathlessness, and fluid retention. It affects around 56 million people globally and is a leading cause of hospitalization and mortality. Its prevalence is rising due to aging populations and lifestyle factors. Managing heart failure demands a multidisciplinary approach, encompassing medications, lifestyle modifications, and often medical devices or surgeries. The treatment burden is substantial, impacting patients’ daily lives and straining healthcare systems. Improving early detection, novel therapies, and patient education are crucial for alleviating the burden and enhancing the quality of life. There are notable advancements in the field of heart failure treatment and prevention. We will discuss significant pharmacological and device advances related to heart failure, including angiotensin receptor–neprilysin inhibitor, sodium–glucose co-transporter inhibition, glucagon-like peptide-1 agonist, cardiac resynchronization therapy, cardiac contractility modulation, mechanical circulatory support devices, and transcatheter valve interventions. We will also review novel therapies on the horizon, emerging technologies like CRISPR-based treatments for genetic anomalies, and the involvement of artificial intelligence in heart failure detection and management.}, year = {2024}, eissn = {2308-3425}, orcid-numbers = {Dhillon, Gagandeep/0000-0002-4780-0537; Sharma, Pranjal/0009-0002-2301-8441; Verma, Ram Kishun/0000-0002-7564-2601; Munjal, Ripudaman/0000-0002-0728-6625; Kashyap, Rahul/0000-0002-4383-3411} } @article{MTMT:34213291, title = {Efficacy and Safety of Empagliflozin According to Background Diuretic Use in Heart Failure With Reduced Ejection Fraction: Post-Hoc Analysis of EMPEROR-Reduced}, url = {https://m2.mtmt.hu/api/publication/34213291}, author = {Dhingra, N.K. and Verma, S. and Butler, J. and Anker, S.D. and Ferreira, J.P. and Filippatos, G. and Januzzi, J.L. and Lam, C.S.P. and Sattar, N. and Zaremba-Pechmann, L. and Böhm, M. and Nordaby, M. and Brueckmann, M. and Pocock, S.J. and Zannad, F. and Packer, M. and EMPEROR-Reduced, Trial Committees and Investigators}, doi = {10.1016/j.jchf.2023.06.036}, journal-iso = {JACC HEART FAILURE}, journal = {JACC-HEART FAILURE}, volume = {12}, unique-id = {34213291}, issn = {2213-1779}, abstract = {Background: The EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) trial established the efficacy of empagliflozin in reducing heart failure (HF) outcomes among patients with heart failure with reduced ejection fraction (HFrEF). Objectives: The authors examined the outcomes of EMPEROR-Reduced as a function of background diuretic therapy. Methods: The EMPEROR-Reduced trial was a double-blind, randomized controlled trial of placebo vs empagliflozin 10 mg among 3,730 HFrEF patients. Herein, the population was stratified into 4 groups: no diuretic and diuretic dose equivalent to furosemide <40, 40, and >40 mg daily at baseline. Results: A total of 3,656 patients from the EMPEROR-Reduced trial were available for analysis. Of those patients, 482 (13.2%) were receiving no diuretic therapy, and 731 (20.0%), 1,411 (38.6%), and 1,032 (28.2%) were receiving <40 mg, 40 mg, and >40 mg, respectively. The efficacy of empagliflozin on the primary outcome (time to first event of hospitalization for HF or cardiovascular [CV] death) was consistent regardless of background diuretic therapy (>40 mg: HR: 0.88 [95% CI: 0.71-1.10]; 40 mg: HR: 0.65 [95% CI: 0.51-0.82]; <40 mg: HR: 0.65 [95% CI: 0.46-0.92]); no diuretic agents: HR: 0.78 [95% CI: 0.47-1.29]; Ptrend test = 0.192). Baseline diuretic doses did not influence the effect of empagliflozin on body weight, systolic blood pressure, NT-proBNP, or hematocrit at 52 weeks. The safety profile of empagliflozin vs placebo was unaffected by baseline diuretic dose; however, independently of treatment allocation, total rates of adverse events were higher among patients with higher baseline doses of diuretic agents. Conclusions: Empagliflozin exhibits a consistent effect on time to CV death or HF hospitalization and an unaltered safety profile regardless of baseline diuretic therapy. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977) © 2023 American College of Cardiology Foundation}, keywords = {heart failure with reduced ejection fraction; Empagliflozin; diuretic agents}, year = {2024}, eissn = {2213-1787}, pages = {35-46} } @article{MTMT:34623846, title = {Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta-analysis}, url = {https://m2.mtmt.hu/api/publication/34623846}, author = {Diallo, A. and Diallo, M. F. and Carlos-Bolumbu, M. and Galtier, F.}, doi = {10.1111/dom.15483}, journal-iso = {DIABETES OBES METAB}, journal = {DIABETES OBESITY & METABOLISM}, volume = {26}, unique-id = {34623846}, issn = {1462-8902}, keywords = {MORTALITY; heart failure; uric acid; sodium-glucose cotransporter 2 inhibitors}, year = {2024}, eissn = {1463-1326}, pages = {1980-1985} } @article{MTMT:34170053, title = {Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review}, url = {https://m2.mtmt.hu/api/publication/34170053}, author = {Dimitrios, P Ntentakis and Victor, San Martin Carvalho Correa and Anastasia, Maria Ntentaki and Eleni, Delavogia and Toshio, Narimatsu and Nikolaos, E Efstathiou and Demetrios, G. Vavvas}, doi = {10.1007/s00417-023-06236-5}, journal-iso = {GRAEF ARCH CLIN EXP}, journal = {GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY}, volume = {262}, unique-id = {34170053}, issn = {0721-832X}, year = {2024}, eissn = {1435-702X}, pages = {717-752} } @article{MTMT:34582826, title = {Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure}, url = {https://m2.mtmt.hu/api/publication/34582826}, author = {Doherty, Daniel J. and Docherty, Kieran F. and Gardner, Roy S.}, doi = {10.1136/heartjnl-2022-322164}, journal-iso = {HEART}, journal = {HEART}, volume = {110}, unique-id = {34582826}, issn = {1355-6037}, abstract = {Guidelines are more accessible than ever and represent an important tool in clinical practice. The National Institute for Health and Care Excellence (NICE) has developed recommendations for heart failure diagnosis and management based not only on morbidity and mortality trial outcome data but also in-depth economic analysis, with a focus on generalisability to UK National Health Service clinical practice. There is broad consistency in structure and content between NICE guidelines and those produced by major cardiovascular organisations such as the American College of Cardiology/American Heart Association and the European Society of Cardiology. However, important differences do exist-largely attributable to publication timing-a factor that is enhanced by the rapid pace of heart failure research. This article reviews the most recent iteration of NICE chronic heart failure guidelines and compares them with major guidelines on an international scale. Variations in recommendations will be explored including implications for NICE guideline updates in the future.}, keywords = {heart failure}, year = {2024}, eissn = {1468-201X}, pages = {466-475} } @article{MTMT:34742587, title = {Estimated Glomerular Filtration Rate and Implantable Cardioverter-Defibrillator in Nonischemic Systolic Heart Failure: Extended Follow-Up of DANISH}, url = {https://m2.mtmt.hu/api/publication/34742587}, author = {Doi, S.N. and Thune, J.J. and Nielsen, J.C. and Haarbo, J. and Videbæk, L. and Yafasova, A. and Bruun, N.E. and Gustafsson, F. and Eiskjær, H. and Hassager, C. and Svendsen, J.H. and Høfsten, D.E. and Torp-Pedersen, C. and Pehrson, S. and Køber, L. and Butt, J.H.}, doi = {10.1161/JAHA.123.031977}, journal-iso = {J AM HEART ASSOC}, journal = {JOURNAL OF THE AMERICAN HEART ASSOCIATION}, volume = {13}, unique-id = {34742587}, issn = {2047-9980}, abstract = {BACKGROUND: Patients with heart failure and chronic kidney disease (CKD) may have an increased risk of death from causes competing with arrhythmic death, which could have implications for the efficacy of implantable cardioverter-defibrillators (ICDs). We examined the long-term effects of primary prophylactic ICD implantation, compared with usual care, according to baseline CKD status in an extended follow-up study of DANISH (Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality). METHODS AND RESULTS: In the DANISH trial, 1116 patients with nonischemic heart failure with reduced ejection fraction were randomized to receive an ICD (N=556) or usual care (N=550). Outcomes were analyzed according to CKD status (estimated glomerular filtration rate ≥/<60 mL/min per 1.73 m2) at baseline. In total, 1113 patients had an available estimated glomerular filtration rate measurement at baseline (median estimated glomerular filtration rate 73 mL/min per 1.73 m2), and 316 (28%) had CKD. During a median follow-up of 9.5 years, ICD implantation, compared with usual care, did not reduce the rate of all-cause mortality (no CKD, HR, 0.82 [95% CI, 0.64–1.04]; CKD, HR, 1.02 [95% CI, 0.75–1.38]; Pinteraction =0.31) or cardiovascular death (no CKD, HR, 0.77 [95% CI, 0.58–1.03]; CKD, HR, 1.05 [95% CI, 0.73–1.51]; Pinteraction =0.20), irrespective of baseline CKD status. Similarly, baseline CKD status did not modify the beneficial effects of ICD implantation on sudden cardiovascular death (no CKD, HR, 0.57 [95% CI, 0.32–1.00]; CKD, HR, 0.65 [95% CI, 0.34–1.24]; Pinteraction =0.70). CONCLUSIONS: ICD implantation, compared with usual care, did not reduce the overall mortality rate, but it did reduce the rate of sudden cardiovascular death, regardless of baseline kidney function in patients with nonischemic heart failure with reduced ejection fraction. © 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.}, keywords = {Follow-Up Studies; Aged; Adult; Female; Middle Aged; Male; Humans; ARTICLE; human; Risk Factors; comparative study; risk factor; confidence interval; major clinical study; controlled study; randomized controlled trial; clinical trial; DENMARK; DENMARK; heart failure; heart failure; heart failure; dipeptidyl carboxypeptidase inhibitor; beta adrenergic receptor blocking agent; chronic kidney failure; chronic kidney failure; glomerulus filtration rate; chronic kidney disease; Glomerular filtration rate; Ventricular Dysfunction, Left; therapy effect; follow up; hazard ratio; Prophylaxis; patient care; clinical effectiveness; Complication; angiotensin receptor antagonist; loop diuretic agent; Cardiovascular mortality; Death, Sudden, Cardiac; SUDDEN CARDIAC DEATH; SUDDEN CARDIAC DEATH; Clinical outcome; Defibrillators, Implantable; amiodarone; Renal Insufficiency, Chronic; thiazide diuretic agent; systolic heart failure; systolic heart failure; heart left ventricle failure; implantable cardioverter defibrillator; Estimated glomerular filtration rate; Estimated glomerular filtration rate; Heart Failure, Systolic; metolazone; all cause mortality; heart failure with reduced ejection fraction; mineralocorticoid antagonist; Implantable cardioverterdefibrillator; Nonischemic systolic heart failure}, year = {2024}, eissn = {2047-9980} } @article{MTMT:34517897, title = {Underrepresentation of Women in Reduced Ejection Heart Failure Clinical Trials With Improved Mortality or Hospitalization}, url = {https://m2.mtmt.hu/api/publication/34517897}, author = {Ekpo, E. and Balla, S. and Ngo, S. and Witting, C. and Sarraju, A. and Furst, A. and Rodriguez, F.}, doi = {10.1016/j.jacadv.2023.100743}, journal-iso = {JACC: ADVANCES}, journal = {JACC: ADVANCES}, volume = {3}, unique-id = {34517897}, abstract = {Background: There are established sex-specific differences in heart failure with reduced ejection fraction (HFrEF) outcomes. Randomized clinical trials (RCTs) based on cardiovascular outcome benefits, typically either reduced cardiovascular mortality or hospitalization for heart failure (HHF), influence current guidelines for therapy. Objectives: The authors evaluate the representation of women in HFrEF RCTs that observed reduced all-cause or cardiovascular mortality or HHF. Methods: We queried Cumulative Index to Nursing and Allied Health Literature, Excerpta Medica dataBASE, Medical Literature Analysis and Retrieval System Online, and PubMed for HFrEF RCTs that reported a statistically significant benefit of intervention resulting in improved mortality or HHF published from 1980 to 2021. We estimated representation using the participation-to-prevalence ratio (PPR). A PPR of 0.8 to 1.2 was considered representative. Results: The final analysis included 33 RCTs. Women represented only 23.2% of all enrolled participants (n = 24,366/104,972), ranging from 11.4% to 40.1% per trial. Overall PPR was 0.58, with per-trial PPR estimates ranging from 0.29 to 1.00. Only 5 trials (15.2%) had a PPR of women representative of the disease population. Representation did not change significantly over time. The proportion of women in North American trials was significantly greater than trials conducted in Europe (P = 0.03). The proportion of women was greater in industry trials compared to government-funded trials (P = 0.05). Conclusions: Women are underrepresented in HFrEF RCTs that have demonstrated mortality or HHF benefits and influence current guidelines. Representation is key to further delineation of sex-specific differences in major trial results. Sustained efforts are warranted to ensure equitable and appropriate inclusion of women in HFrEF trials. © 2024 The Authors}, keywords = {REPRESENTATION; WOMEN; heart failure; Heart failure reduced ejection fraction}, year = {2024}, eissn = {2772-963X} } @article{MTMT:34434947, title = {The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review}, url = {https://m2.mtmt.hu/api/publication/34434947}, author = {EL-Andari, R. and Fialka, N.M. and Kang, J. and Bozso, S.J. and Nagendran, J. and Nagendran, J.}, doi = {10.1007/s40256-023-00618-0}, journal-iso = {AM J CARDIOVASC DRUG}, journal = {AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS}, volume = {24}, unique-id = {34434947}, issn = {1175-3277}, year = {2024}, eissn = {1179-187X}, pages = {55-69} } @article{MTMT:34536412, title = {Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective}, url = {https://m2.mtmt.hu/api/publication/34536412}, author = {Elkeraie, A.F. and Al-Ghamdi, S. and Abu-Alfa, A.K. and Alotaibi, T. and Alsaedi, A.J. and Alsuwaida, A. and Arici, M. and Ecder, T. and Ghnaimat, M. and Hafez, M.H. and Hassan, M.H. and Sqalli, T.}, doi = {10.2147/IJNRD.S430532}, journal-iso = {INT J NEPHROL RENOVASC DIS}, journal = {INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE}, volume = {17}, unique-id = {34536412}, abstract = {Chronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD. © 2024 Elkeraie et al.}, keywords = {ARTICLE; DIABETIC NEUROPATHY; human; diabetes mellitus; HYPERTENSION; OBESITY; microalbuminuria; diabetic retinopathy; proteinuria; cardiovascular disease; unclassified drug; chronic kidney failure; glomerulus filtration rate; creatinine blood level; chronic kidney disease; renin angiotensin aldosterone system; nephrolithiasis; nephrotic syndrome; URINARY TRACT INFECTION; Screening; urinary tract obstruction; organ transplantation; protein inhibitor; non insulin dependent diabetes mellitus; dipeptidyl peptidase IV inhibitor; Clinical outcome; Hyperparathyroidism; hyperkalemia; electrolyte disturbance; randomized controlled trial (topic); urolithiasis; potassium blood level; Coronary atherosclerosis; Concentration ratio; End stage renal disease; Estimated glomerular filtration rate; all cause mortality; heart failure with reduced ejection fraction; resistant hypertension; dapagliflozin; Empagliflozin; Canagliflozin; ertugliflozin; sodium-glucose cotransporter-2 inhibitors; Sodium glucose cotransporter 2 inhibitor; Nephrology referral; sotagliflozin; sodium glucose cotransporter 1; renin angiotensin aldosterone system inhibitor; urine albumin creatinine ratio}, year = {2024}, eissn = {1178-7058}, pages = {1-16} } @article{MTMT:34536399, title = {SGLT2 inhibitors in heart failure with preserved ejection fraction}, url = {https://m2.mtmt.hu/api/publication/34536399}, author = {Faluk, M. and Wardhere, A. and Thakker, R. and Khan, F.A.}, doi = {10.1016/j.cpcardiol.2024.102388}, journal-iso = {CURR PROB CARDIOLOGY}, journal = {CURRENT PROBLEMS IN CARDIOLOGY}, volume = {49}, unique-id = {34536399}, issn = {0146-2806}, abstract = {Heart failure (HF) is a clinical syndrome due to either functional or structural impairment of the ventricular pump or filling, representing a major cause of global morbidity and mortality. Heart failure with preserved ejection fraction (HFpEF), characterized by a left ventricular ejection fraction (LVEF) of ≥50%, constitutes over half of the HF population, with a rising prevalence. Until recently, therapeutic options in treating HFpEF and reducing hospitalization and mortality remained limited. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promising results in this patient population. This review article explores current literature and significant clinical trials investigating the impact of sodium- SGLT2 inhibitors in patients with HFpEF. © 2024 Elsevier Inc.}, keywords = {review; human; Quality of Life; hospitalization; Exercise; placebo; disease exacerbation; follow up; non insulin dependent diabetes mellitus; Cardiovascular mortality; clinical trial (topic); Estimated glomerular filtration rate; Patient-reported outcome; Heart failure with preserved ejection fraction; dapagliflozin; Empagliflozin; Sodium glucose cotransporter 2 inhibitor}, year = {2024}, eissn = {1535-6280} } @article{MTMT:34742623, title = {The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices}, url = {https://m2.mtmt.hu/api/publication/34742623}, author = {Fardman, A. and Kodesh, A. and Siegel, A.J. and Segev, A. and Regev, E. and Maor, E. and Berkovitch, A. and Kuperstein, R. and Morgan, A. and Nahum, E. and Peled, Y. and Grupper, A.}, doi = {10.1111/aor.14733}, journal-iso = {ARTIF ORGANS}, journal = {ARTIFICIAL ORGANS}, volume = {In press}, unique-id = {34742623}, issn = {0160-564X}, abstract = {Background: The safety and impact of sodium glucose transporter 2 inhibitors (SGLT2-I) in patients with left ventricular assist devices (LVAD) are unknown. Methods: A retrospective analysis of all consecutive patients who underwent LVAD Heart Mate 3 (HM3) implantation at a single medical center and received SGLT2-I therapy following surgery was conducted. LVAD parameters, medical therapy, laboratory tests, echocardiography, and right heart catheterization (RHC) study results were recorded and compared before and after initiation of SGLT2-I. Results: SGLT2-I medications were initiated in 29 (21%) of 138 patients following HM3 implantation (23 (79%) received Empagliflozin and 6 (21%) Dapagliflozin). The mean age at the time of LVAD implantation was 62 ± 6.7 years, 25 (86%) were male, and 23 (79%) had diabetes mellitus. The median time from HM3 implantation to SGLT2-I initiation was 108 days, IQR (26–477). Following SGLT2-I therapy, the daily dose of furosemide decreased from 47 to 23.5 mg/day (mean difference = 23.5 mg/d, 95% CI 8.2–38.7, p = 0.004) and significant weight reduction was observed (mean difference 2.5 kg, 95% CI 0.7–4.3, p = 0.008). Moreover, a significant 5.6 mm Hg reduction in systolic pulmonary artery pressure (sPAP) was measured during RHC (95% CI 0.23–11, p = 0.042) in a subgroup of 11 (38%) patients. LVAD parameters were similar before and after SGLT2-I initiation (p > 0.2 for all). No adverse events were recorded during median follow-up of 354 days, IQR (206–786). Conclusion: SGLT2-I treatment is safe in LVAD patients and might contribute to reduction in patients sPAP. © 2024 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.}, keywords = {Blood Pressure; SAFETY; SODIUM; GLUCOSE; Echocardiography; HYDROGEN-TRANSFER REDUCTIONS; Heart Catheterization; Pulmonary Artery; Diuretics; Patient treatment; Clinical parameters; Pulmonary artery pressure; Pulmonary artery pressure; Glucose transporters; Diuretic; Left ventricular assist devices; LVAD; sodium glucose transporter 2 inhibitor; SGLT2-i; Artery pressure; Device parameters}, year = {2024}, eissn = {1525-1594} } @article{MTMT:34143925, title = {Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial}, url = {https://m2.mtmt.hu/api/publication/34143925}, author = {Fauchier, L. and Lamblin, N. and Tardu, J. and Bellier, L. and Groyer, H. and Ittah, D. and Chollet, J. and Linden, S. and Levy, P.}, doi = {10.1007/s41669-023-00432-z}, journal-iso = {PHARMACOECON-OPEN}, journal = {PHARMACOECONOMICS-OPEN}, volume = {8}, unique-id = {34143925}, issn = {2509-4262}, abstract = {Introduction: The efficacy and safety of empagliflozin in the treatment of heart failure with preserved ejection fraction (HFpEF) were demonstrated in the EMPEROR-Preserved trial, which showed a 21% reduction in combined risks of cardiovascular death or HF hospitalization [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.69–0.90, p < 0.001] and a 27% reduction in the total number of HF hospitalizations (HR 0.73; 95% CI 0.61–0.88, p < 0.001) compared with placebo. On the basis of these results, the present study aimed to assess the cost-effectiveness of empagliflozin + standard of care (SoC) compared with SoC alone in the treatment of HFpEF. Methods: A published Markov model was adapted to compare the health and economic outcomes in France, considering a collective perspective, in patients treated with empagliflozin in addition to SoC versus patients treated by SoC alone. The model simulated the intention-to-treat (ITT) population of the trial, transitioning between four mutually exclusive health states representing the quartiles of the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS). For each arm, the model estimated (over a lifetime time horizon) the economics and the health outcomes (HF hospitalizations avoided, and life years and quality-adjusted life years (QALYs) gained) to calculate the incremental cost-effectiveness ratios (ICERs). The resources used were derived by pairing the FREnch Survey on HF (FRESH) cohort data to French health insurance claims data, and the utilities were derived on the basis of the EQ-5D-5L questionnaire valued on the French tariff. Both economic and health outcomes were discounted at a 2.5% annual rate. Results: The model predicted that treatment of HFpEF patients with empagliflozin would prevent, for 1000 patients treated, 74 HF hospitalizations and 15 deaths attributable to cardiovascular events, resulting on average in a gain of 1 month in overall survival (7.24 versus 7.16 years with placebo) and 0.11 QALYs (6.14 versus 6.03 with placebo). Empagliflozin costs were partially offset by the cost savings from avoided hospitalizations. The ICERs were €18,597 per life year gained and €13,980 per QALY gained. The sensitivity analyses conducted showed that empagliflozin has a 65% probability to be cost-effective under the €25,000/QALY threshold. Conclusions: The base-case results showed that empagliflozin is a cost-effective strategy for management of HFpEF, in addition to the impact on public health by preventing HF-hospitalizations and deaths in France. Sensitivity analyses suggest that 65% of simulations are under the €25,000/QALY threshold. © 2023, The Author(s).}, year = {2024}, eissn = {2509-4254}, pages = {19-30} } @article{MTMT:34639861, title = {Gender Effect on Clinical Profiles, Pharmacological Treatments and Prognosis in Patients Hospitalized for Heart Failure}, url = {https://m2.mtmt.hu/api/publication/34639861}, author = {Fazzini, Luca and Casati, Mattia and Martis, Alessandro and Perra, Ferdinando and Rubiolo, Paolo and Deidda, Martino and Mercuro, Giuseppe and Cadeddu Dessalvi, Christian}, doi = {10.3390/jcm13030881}, journal-iso = {J CLIN MED}, journal = {JOURNAL OF CLINICAL MEDICINE}, volume = {13}, unique-id = {34639861}, keywords = {Prognosis; acute heart failure; gender medicine; pharmacological treatments}, year = {2024}, eissn = {2077-0383}, orcid-numbers = {Deidda, Martino/0000-0002-3725-7614} } @article{MTMT:34766745, title = {Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme}, url = {https://m2.mtmt.hu/api/publication/34766745}, author = {Ferreira, J.P. and Packer, M. and Sattar, N. and Butler, J. and Pocock, S.J. and Anker, S.D. and Maldonado, S.G. and Panova-Noeva, M. and Sumin, M. and Masson, S. and Zannad, F. and Januzzi, J.L.}, doi = {10.1002/ejhf.3166}, journal-iso = {EUR J HEART FAIL}, journal = {EUROPEAN JOURNAL OF HEART FAILURE}, volume = {In press}, unique-id = {34766745}, issn = {1388-9842}, abstract = {Aim: Vascular congestion may lead to an increase of carbohydrate antigen 125 (CA-125). The role of CA-125 as a biomarker of congestion or for prognosis across the full ejection fraction (EF) spectrum of chronic heart failure (HF) remains unknown. Methods and results: Serum CA-125 was measured in 1111 study participants from the EMPEROR-Reduced and EMPEROR-Preserved trials. Congestive signs and symptoms were evaluated across CA-125 tertiles. Cox regression was used to study the association with outcomes. The primary outcome was a composite of first HF hospitalization or cardiovascular (CV) death. No significant association was present between baseline CA-125 levels and congestive signs or symptoms. In the overall population, higher CA-125 levels were not associated with an increased risk of primary outcome (tertile 3 vs. tertile 1: hazard ratio [HR] 1.34; 95% confidence interval [CI] 0.91–1.96; p-trend = 0.11). However, higher CA-125 levels were associated with an increased risk of primary outcome in patients with HF and reduced EF (HFrEF; tertile 3 vs. tertile 1: HR 2.25 [95% CI 1.30–3.89]), but not among patients with preserved EF (HFpEF; tertile 3 vs. tertile 1: HR 0.68 [95% CI 0.38–1.21]); interaction-p = 0.02). Patients in the upper CA-125 tertile also showed the steepest estimated glomerular filtration rate decline over time (p-trend = 0.03). The effect of empagliflozin to reduce the risk of CV death or HF hospitalization appeared to be attenuated in those with lower baseline CA-125 levels (interaction-p-trend = 0.09). Conclusion: Across the range of EF in patients with chronic HF enrolled in the EMPEROR trials, the majority of whom did not have clinical evidence of congestion, CA-125 concentrations were not significantly associated with congestive signs or symptoms. CA-125 concentrations may predict HF hospitalization/CV death in patients with HFrEF, but not those with HFpEF. Clinical Trial Registration: EMPEROR-Reduced (NCT03057977), EMPEROR-Preserved (NCT03057951). © 2024 European Society of Cardiology.}, keywords = {heart failure; kidney function; Congestion; Empagliflozin; Diuretic; CA-125}, year = {2024}, eissn = {1879-0844}, pages = {In press} } @article{MTMT:34777747, title = {Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches}, url = {https://m2.mtmt.hu/api/publication/34777747}, author = {Frățilă, V.-G. and Lupușoru, G. and Sorohan, B.M. and Obrișcă, B. and Mocanu, V. and Lupușoru, M. and Ismail, G.}, doi = {10.3390/biomedicines12030569}, journal-iso = {BIOMEDICINES}, journal = {BIOMEDICINES}, volume = {12}, unique-id = {34777747}, year = {2024}, eissn = {2227-9059} } @article{MTMT:34742632, title = {Prognostic Impact of Reduced Left Ventricular Ejection Fraction After Endovascular Therapy for Lower Extremities}, url = {https://m2.mtmt.hu/api/publication/34742632}, author = {Fukino, K. and Ueshima, D. and Yamaguchi, T. and Mizuno, A. and Tobita, K. and Suzuki, K. and Murata, N. and Jujo, K. and Kodama, T. and Nakamura, F. and Higashitani, M.}, doi = {10.1253/circj.CJ-23-0215}, journal-iso = {CIRC J}, journal = {CIRCULATION JOURNAL: OFFICIAL JOURNAL OF THE JAPANESE CIRCULATION SOCIETY}, volume = {88}, unique-id = {34742632}, issn = {1346-9843}, abstract = {Background: The mechanism underlying a poor prognosis in patients with lower-extremity artery disease (LEAD) with heart failure is unknown. We examined the prognostic impact of the left ventricular ejection fraction (LVEF) in patients with LEAD who underwent endovascular therapy (EVT). Methods and Results: From August 2014 to August 2016, 2,180 patients with LEAD (mean age, 73.2 years; male, 71.9%) underwent EVT and were stratified into low-LVEF (LVEF <40%; n=234, 10.7%) and not-low LVEF groups. In the low- vs. not-low LVEF groups, there was a higher prevalence of heart failure (i.e., history of heart failure hospitalization or New York Heart Association functional class III or IV symptoms) (44.0% vs. 8.3%, respectively), diabetes mellitus, chronic kidney disease, below-the-knee lesion, critical limb ischemia, and incidence of major cardiovascular and cerebrovascular events (MACCEs) and major adverse limb events (MALEs) (P<0.001, all). Low LVEF independently predicted MACCEs (hazard ratio: 2.23, 95% confidence interval: 1.63–3.03; P<0.001) and MALEs (hazard ratio: 1.85, 95% confidence interval: 1.15–2.96; P=0.011), regardless of heart failure (P value for interaction: MACCEs: 0.27; MALEs: 0.52). Conclusions: Low LVEF, but not symptomatic heart failure, increased the incidence of MACCEs and MALEs. Intensive cardiac dysfunction management may improve LEAD prognosis after EVT. © 2024 Japanese Circulation Society. All rights reserved.}, keywords = {Aged; Aged; Female; Male; Male; Humans; ARTICLE; human; diabetes mellitus; Prognosis; Prognosis; Prognosis; inflammatory disease; major clinical study; cohort analysis; HEMOGLOBIN; HYPERTENSION; INSULIN; information processing; hospitalization; cerebrovascular accident; biological marker; Echocardiography; Leukocyte Count; Platelet Count; IMPLANTATION; heart failure; heart failure; heart failure; heart failure; heart arrhythmia; albumin; beta adrenergic receptor blocking agent; dyslipidemia; body mass; triacylglycerol; prospective study; chronic kidney failure; cerebrovascular disease; Ventricular Dysfunction, Left; heart left ventricle function; cholesterol blood level; lactate dehydrogenase; ischemic heart disease; coronary artery disease; acetylsalicylic acid; Lower Extremity; ENDARTERECTOMY; electrocardiogram; creatine kinase; heart infarction; C reactive protein; follow up; Stroke Volume; aspartate aminotransferase; angiotensin receptor antagonist; calcium channel blocking agent; Ventricular Function, Left; chronic obstructive lung disease; alanine aminotransferase; artery disease; Thrombectomy; SUDDEN CARDIAC DEATH; STENT IMPLANTATION; anticoagulant agent; Clinical outcome; icosapentaenoic acid; heart left ventricle ejection fraction; heart stroke volume; Amputation; troponin; Aortic valve stenosis; CRITICAL LIMB ISCHEMIA; Atrial Fibrillation; limb ischemia; Ankle Brachial Index; heart left ventricle failure; endovascular surgery; tricuspid valve disease; thienopyridine derivative; cilostazol; Endovascular Procedures; Endovascular therapy; vertebral canal stenosis; Acute limb ischemia; lower limb; target lesion revascularization; statin (protein); claudication; bypass surgery; lower extremity artery disease; LEFT VENTRICULAR EJECTION FRACTION; limb perfusion; Femoropopliteal bypass; Lower-extremity artery disease; Cardiac dysfunction management}, year = {2024}, eissn = {1347-4820}, pages = {341-350} } @article{MTMT:34747986, title = {Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure}, url = {https://m2.mtmt.hu/api/publication/34747986}, author = {Gallo, G. and Volpe, M.}, doi = {10.3390/ijms25052484}, journal-iso = {INT J MOL SCI}, journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES}, volume = {25}, unique-id = {34747986}, issn = {1661-6596}, abstract = {Different multifactorial pathophysiological processes are involved in the development of heart failure (HF), including neurohormonal dysfunction, the hypertrophy of cardiomyocytes, interstitial fibrosis, microvascular endothelial inflammation, pro-thrombotic states, oxidative stress, decreased nitric oxide (NO) bioavailability, energetic dysfunction, epicardial coronary artery lesions, coronary microvascular rarefaction and, finally, cardiac remodeling. While different pharmacological strategies have shown significant cardiovascular benefits in HF with reduced ejection fraction (HFrEF), there is a residual unmet need to fill the gap in terms of knowledge of mechanisms and efficacy in the outcomes of neurohormonal agents in HF with preserved ejection fraction (HFpEF). Recently, type-2 sodium–glucose transporter inhibitors (SGLT2i) have been shown to contribute to a significant reduction in the composite outcome of HF hospitalizations and cardiovascular mortality across the entire spectrum of ejection fraction. Moreover, glucagon-like peptide-1 receptor agonists (GLP1-RA) have demonstrated significant benefits in patients with high cardiovascular risk, excess body weight or obesity and HF, in particular HFpEF. In this review, we will discuss the biological pathways potentially involved in the action of SGLT2i and GLP1-RA, which may explain their effective roles in the treatment of HF, as well as the potential implications of the use of these agents, also in combination therapies with neurohormonal agents, in the clinical practice. © 2024 by the authors.}, keywords = {Humans; SODIUM; SODIUM; human; heart failure; heart failure; heart failure; Stroke Volume; Myocytes, Cardiac; glucose transporter; heart stroke volume; cardiac muscle cell; SGLT2i; glucagon-like peptide-1 receptor agonists; heart failure management; Glucose Transport Proteins, Facilitative; GLP1-RA; cardiometabolic drugs}, year = {2024}, eissn = {1422-0067} } @article{MTMT:34795700, title = {SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure: A Systematic Review and Meta-Analysis}, url = {https://m2.mtmt.hu/api/publication/34795700}, author = {Gao, M. and Bhatia, K. and Kapoor, A. and Badimon, J. and Pinney, S.P. and Mancini, D.M. and Santos-Gallego, C.G. and Lala, A.}, doi = {10.1001/jamanetworkopen.2024.5135}, journal-iso = {JAMA NETW OPEN}, journal = {JAMA NETWORK OPEN}, volume = {7}, unique-id = {34795700}, abstract = {Importance: The associations of sodium glucose cotransporter-2 inhibitors (SGLT2is) with reduction in mortality and hospitalization rates in patients with heart failure (HF) are well established. However, their association with improving functional capacity and quality of life (QOL) has been variably studied and less reported. Objective: To provide evidence on the extent to which SGLT2is are associated with improvement on objective measures of functional capacity and QOL in patients living with HF. Data Sources: The MEDLINE, EMBASE, and Cochrane databases were systematically searched for relevant articles on July 31, 2023. Study Selection: Randomized, placebo-controlled clinical trials reporting the effect of SGLT2i on functional outcomes of exercise capacity (peak oxygen consumption [peak VO2] or 6-minute walk distance [6MWD]) and/or QOL using validated questionnaires for patients with HF were included. Data Extraction and Synthesis: Data were extracted by 2 authors following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, and a meta-analysis using the restricted maximum likelihood random-effects model was conducted. Main Outcomes and Measures: Outcomes of interest included changes in peak VO2, 6MWD, and Kansas City Cardiomyopathy Questionnaire-12 total symptom score (KCCQ-TSS), clinical summary score (KCCQ-CSS), and overall summary score (KCCQ-OSS). Results: In this meta-analysis of 17 studies, 23523 patients (mean [range] age, 69 [60-75] years) were followed over a period ranging from 12 to 52 weeks. Four studies included peak VO2 as an outcome, 7 studies included 6MWD, and 10 studies reported KCCQ scores. Mean (SD) left ventricular ejection fraction was 43.5% (12.4%). Compared with controls, patients receiving SGLT2i treatment experienced significant increases in peak VO2 (mean difference [MD], 1.61 mL/kg/min; 95% CI, 0.59-2.63 mL/kg/min; P =.002) and 6MWD (MD, 13.09 m; 95% CI, 1.20-24.97 m; P =.03). SGLT2i use was associated with increased KCCQ-TSS (MD, 2.28 points; 95% CI, 1.74-2.81 points; P <.001), KCCQ-CSS (MD, 2.14 points; 95% CI, 1.53-2.74 points; P <.001), and KCCQ-OSS (MD, 1.90 points; 95% CI, 1.41-2.39 points; P <.001) scores. Subgroup analysis and meta-regression demonstrated almost all improvements were consistent across ejection fraction, sex, and the presence of diabetes. Conclusions and Relevance: These findings suggest that in addition to known clinical associations with mortality and hospitalization outcomes, SGLT2i use is associated with improvement in outcomes of interest to patients' everyday lives as measured by objective assessments of maximal exercise capacity and validated QOL questionnaires, regardless of sex or ejection fraction. © 2024 American Medical Association. All rights reserved.}, keywords = {Aged; Aged; Humans; human; Quality of Life; Quality of Life; heart failure; heart failure; heart left ventricle function; meta analysis; Stroke Volume; Ventricular Function, Left; heart stroke volume; Sodium glucose cotransporter 2 inhibitor; Sodium-glucose transporter 2 inhibitors}, year = {2024}, eissn = {2574-3805}, pages = {E245135} } @article{MTMT:34750146, title = {A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials}, url = {https://m2.mtmt.hu/api/publication/34750146}, author = {García-Moll, X. and Croci, F. and Solé, A. and Hartgers-Gubbels, E.S. and Calleja-Hernández, M.A.}, doi = {10.1080/14779072.2024.2324027}, journal-iso = {EXP REV CARDIOVASC THER}, journal = {EXPERT REVIEW OF CARDIOVASCULAR THERAPY}, volume = {In press}, unique-id = {34750146}, issn = {1477-9072}, abstract = {Background: Heart failure (HF) is a chronic condition with considerable clinical burden for patients and economic burden for healthcare systems. Treatment for HF is typically based on ejection fraction (EF) phenotype. The cost-effectiveness of empagliflozin + standard of care (SoC) compared to SoC has been examined for HF phenotypes below or above 40% EF separately, but not across the full spectrum of EF in Spain. Methods: The results of two preexisting, validated, and published phenotype-specific Markov cohort models were combined using a population-weighted approach, reflecting the incidence of each phenotype in the total HF population in Spain. A probabilistic sensitivity analysis was performed by sampling each model’s probabilistic results. Results: Empagliflozin + SoC compared to SoC resulted in increased life-years (LYs) (6.48 vs. 6.35), quality-adjusted LYs (QALYs) (4.80 vs. 4.63), and healthcare costs (€19,090 vs. €18,246), over a lifetime time horizon for the combined HF population in Spain. The incremental cost-effectiveness ratio (ICER) was €5,089/QALY. All subgroup, scenario, and probabilistic ICERs were consistently below €10,000/QALY. Conclusions: Empagliflozin is the first treatment with established efficacy and cost-effectiveness for HF patients across EF from the perspective of healthcare payers in Spain. Empagliflozin also proved to be cost-effective for all subgroups of patients included in the analysis. © 2024 I am not an employee but the copyright belongs to Boehringer Ingelheim International GmbH. Published by Informa UK Limited, trading as Taylor & Francis Group.}, keywords = {Spain; heart failure; Cost-effectiveness; EJECTION FRACTION; Empagliflozin; SGLT INHIBITORS}, year = {2024}, eissn = {1744-8344} } @article{MTMT:34423918, title = {Assessing Cardiac Contractility From Single Molecules to Whole Hearts}, url = {https://m2.mtmt.hu/api/publication/34423918}, author = {Garg, A. and Lavine, K.J. and Greenberg, M.J.}, doi = {10.1016/j.jacbts.2023.07.013}, journal-iso = {JACC-BASIC TRANSL SC}, journal = {JACC:BASIC TO TRANSLATIONAL SCIENCE}, volume = {9}, unique-id = {34423918}, issn = {2452-302X}, year = {2024}, eissn = {2452-302X}, pages = {414-439} } @article{MTMT:34649627, title = {Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure}, url = {https://m2.mtmt.hu/api/publication/34649627}, author = {Gass, Alan}, doi = {10.1016/j.amjmed.2023.04.032}, journal-iso = {AM J MED}, journal = {AMERICAN JOURNAL OF MEDICINE}, volume = {137}, unique-id = {34649627}, issn = {0002-9343}, year = {2024}, eissn = {1555-7162}, pages = {S1-S2} } @article{MTMT:34434785, title = {Application of eligibility criteria from DAPA-HF, EMPEROR-Reduced, and PARADIGM-HF trials to a population with heart failure with reduced ejection fraction at a specialized cardiology Clinic in Medellin, Colombia: A retrospective cohort study}, url = {https://m2.mtmt.hu/api/publication/34434785}, author = {Gonzalez-Franco, J. and Caicedo-Espinosa, J. and Cardona-Tobon, C. and Jaramillo-Jara, N. and Aguilar-Molina, O. and Jaimes-Barragan, F.-A. and Saldarriaga-Giraldo, C.-I.}, doi = {10.1016/j.cpcardiol.2023.102193}, journal-iso = {CURR PROB CARDIOLOGY}, journal = {CURRENT PROBLEMS IN CARDIOLOGY}, volume = {49}, unique-id = {34434785}, issn = {0146-2806}, year = {2024}, eissn = {1535-6280} } @article{MTMT:34517147, title = {Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure}, url = {https://m2.mtmt.hu/api/publication/34517147}, author = {Greene, S.J. and Butler, J. and Kosiborod, M.N.}, doi = {10.1016/j.amjmed.2023.04.019}, journal-iso = {AM J MED}, journal = {AMERICAN JOURNAL OF MEDICINE}, volume = {137}, unique-id = {34517147}, issn = {0002-9343}, abstract = {Cardiovascular outcomes trials of sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated consistent signals of benefit in terms of both prevention and treatment of heart failure (HF), in patients with and without type 2 diabetes (T2D). In response to growing evidence of the benefits of SGLT2 inhibitors, including increased survival, reduced hospitalizations and improved patient-reported symptoms, functional status, and quality of life, the treatment landscape for HF has evolved. Importantly, these agents have also demonstrated safety and tolerability in individuals with HF across the spectrum of left ventricular ejection fraction, with improvements in clinical and patient-reported outcomes occurring as early as days to weeks after treatment initiation. For patients with heart failure with reduced ejection fraction (HFrEF), SGLT2 inhibitors are now increasingly recognized as foundational disease-modifying therapy. An updated joint guideline from the American College of Cardiology and American Heart Association now recommends including SGLT2 inhibitors for patients with HF across the spectrum of ejection fraction, irrespective of the presence of diabetes, and regardless of background therapy (Class 1 recommendation for HFrEF, Class 2a recommendation for HF with mildly reduced ejection fraction [HFmrEF] and HF with preserved ejection fraction [HFpEF]). The European Society of Cardiology also include a Class I recommendation to use SGLT2 inhibitors for patients with HFrEF to reduce the risk of hospitalization for HF and CV death, irrespective of T2D status. This chapter reviews published clinical trial data about the efficacy and safety of SGLT2 inhibitors among patients with HFrEF, HFpEF, and patients hospitalized for HF. © 2023}, keywords = {Humans; SODIUM; SODIUM; human; Quality of Life; Quality of Life; GLUCOSE; GLUCOSE; hospitalization; United States; United States; heart failure; heart failure; heart failure; Diabetes Mellitus, Type 2; heart left ventricle function; Stroke Volume; Complication; non insulin dependent diabetes mellitus; Ventricular Function, Left; heart stroke volume; Symporters; cotransporter; CARDIOVASCULAR OUTCOMES; Sodium-glucose co-transporter 2 inhibitors; Sodium glucose cotransporter 2 inhibitor; Sodium-glucose transporter 2 inhibitors}, year = {2024}, eissn = {1555-7162}, pages = {S25-S34} } @article{MTMT:34774113, title = {Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)}, url = {https://m2.mtmt.hu/api/publication/34774113}, author = {Green, J.B. and Everett, B.M. and Ghosh, A. and Younes, N. and Krause-Steinrauf, H. and Barzilay, J. and Desouza, C. and Inzucchi, S.E. and Pokharel, Y. and Schade, D. and Scrymgeour, A. and Tan, M.H. and Utzschneider, K.M. and Mudaliar, S. and Crandall, J.P. and McKee, M.D. and Behringer-Massera, S. and Brown-Friday, J. and Xhori, E. and Ballentine-Cargill, K. and Duran, S. and Estrella, H. and Gonzalez, De La Torre S. and Lukin, J. and Phillips, L.S. and Burgess, E. and Olson, D. and Rhee, M. and Wilson, P. and Raines, T.S. and Boers, J. and Costello, J. and Maher-Albertelli, M. and Mungara, R. and Savoye, L. and White, C.A. and Gullett, C. and Holloway, L. and Morehead, F. and Person, S. and Sibymon, M. and Tanukonda, S. and Adams, C. and Ross, A. and Balasubramanyam, A. and Gaba, R. and Gonzalez, Hattery E. and Ideozu, A. and Jimenez, J. and Montes, G. and Wright, C. and Hollander, P. and Roe, E. and Jackson, A. and Smiley, A. and Burt, P. and Estrada, L. and Chionh, K. and Ismail-Beigi, F. and Falck-Ytter, C. and Sayyed, Kassem L. and Sood, A. and Tiktin, M. and Kulow, T. and Newman, C. and Stancil, K.A. and Cramer, B. and Iacoboni, J. and Kononets, M.V. and Sanders, C. and Tucker, L. and Werner, A. and Maxwell, A. and McPhee, G. and Patel, C. and Colosimo, L. and Krol, A. and Goland, R. and Pring, J. and Alfano, L. and Kringas, P. and Hausheer, C. and Tejada, J. and Gumpel, K. and Kirpitch, A. and Schneier, H. and Abouassi, H. and Chatterjee, R. and Feinglos, M.N. and English, Jones J. and Khan, S.A. and Kimpel, J.B. and Zimmer, R.P. and Furst, M. and Satterwhite, B.M. and Thacker, C.R. and Evans, Kreider K. and Mariash, C.N. and Mather, K.J. and Ismail, H.M. and Lteif, A. and Mullen, M. and Hamilton, T. and Patel, N. and Riera, G. and Jackson, M. and Pirics, V. and Aguillar, D. and Howard, D. and Hurt, S. and Bergenstal, R. and Carlson, A. and Martens, T. and Johnson, M. and Hill, R. and Hyatt, J. and Jensen, C. and Madden, M. and Martin, D. and Willis, H. and Konerza, W. and Yang, S. and Kleeberger, K. and Passi, R. and Fortmann, S. and Herson, M. and Mularski, K. and Glauber, H. and Prihoda, J. and Ash, B. and Carlson, C. and Ramey, P.A. and Schield, E. and Torgrimson-Ojerio, B. and Arnold, K. and Kauffman, B. and Panos, E. and Sahnow, S. and Bays, K. and Berame, K. and Cook, J. and Ghioni, D. and Gluth, J. and Schell, K. and Criscola, J. and Friason, C. and Jones, S. and Nazarov, S. and Rassouli, N. and Puttnam, R. and Ojoawo, B. and Nelson, R. and Curtis, M. and Hollis, B. and Sanders-Jones, C. and Stokes, K. and El-Haqq, Z. and Kolli, A. and Tran, T. and Wexler, D. and Larkin, M.E. and Meigs, J. and Chambers, B. and Dushkin, A. and Rocchio, G. and Yepes, M. and Steiner, B. and Dulin, H. and Cayford, M. and Chu, K. and Demanbey, A. and Hillard, M. and Martin, K. and Thangthaeng, N. and Gurry, L. and Kochis, R. and Raymond, E. and Ripley, V. and Stevens, C. and Park, J. and Aroda, V. and Ghazi, A. and Magee, M. and Ressing, A. and Loveland, A. and Hamm, M. and Hurtado, M. and Kuhn, A. and Leger, J. and Manandhar, L. and Mwicigi, F. and Sanchez, O. and Young, T. and Garg, R. and Lagari-Libhaber, V. and Florez, H.J. and Valencia, W.M. and Marks, J. and Casula, S. and Oropesa-Gonzalez, L. and Hue, L. and Cuadot, A. and Nieto-Martinez, R. and Riccio, Veliz A.K. and Gutt, M. and Kendal, Y.J. and Veciana, B. and Ahmann, A. and Aby-Daniel, D. and Joarder, F. and Morimoto, V. and Sprague, C. and Yamashita, D. and Cady, N. and Rivera-Eschright, N. and Kirchhoff, P. and Morales, Gomez B. and Adducci, J. and Goncharova, A. and Hox, S.H. and Petrovitch, H. and Matwichyna, M. and Jenkins, V. and Broadwater, L. and Ishii, R.R. and Bermudez, N.O. and Hsia, D.S. and Cefalu, W.T. and Greenway, F.L. and Waguespack, C. and King, E. and Fry, G. and Dragg, A. and Gildersleeve, B. and Arceneaux, J. and Haynes, N. and Thomassie, A. and Pavlionis, M. and Bourgeois, B. and Hazlett, C. and Henry, R. and Boeder, S. and Pettus, J. and Diaz, E. and Garcia-Acosta, D. and Maggs, S. and Delue, C. and Stallings, A. and Castro, E. and Hernandez, S. and Krakoff, J. and Curtis, J.M. and Killean, T. and Khalid, M. and Joshevama, E. and Diaz, E. and Martin, D. and Tsingine, K. and Karshner, T. and Albu, J. and Pi-Sunyer, F.X. and Frances, S. and Maggio, C. and Ellis, E. and Bastawrose, J. and Gong, X. and Banerji, M.A. and August, P. and Lee, M. and Lorber, D. and Brown, N.M. and Josephson, D.H. and Thomas, L.L. and Tsovian, M. and Cherian, A. and Jacobson, M.H. and Mishko, M.M. and Kirkman, M.S. and Buse, J.B. and Diner, J. and Dostou, J. and MacHineni, S. and Young, L. and Bergamo, K. and Goley, A. and Kerr, J. and Largay, J.F. and Guarda, S. and Cuffee, J. and Culmer, D. and Fraser, R. and Almeida, H. and Coffer, S. and Debnam, E. and Kiker, L. and Morton, S. and Josey, K. and Fuller, G. and Garvey, W.T. and Cherrington, A.L. and Dyer, D. and Lawson, M.C.R. and Griffith, O. and Agne, A. and McCullars, S. and Cohen, R.M. and Craig, J. and Rogge, M.C. and Burton, K. and Kersey, K. and Wilson, C. and Lipp, S. and Vonder, Meulen M.B. and Adkins, C. and Onadeko, T. and Rasouli, N. and Baker, C. and Schroeder, E. and Razzaghi, M. and Lyon, C. and Penaloza, R. and Underkofler, C. and Lorch, R. and Douglass, S. and Steiner, S. and Sivitz, W.I. and Cline, E. and Knosp, L.K. and McConnell, J. and Lowe, T. and Herman, W.H. and Pop-Busui, R. and Martin, C. and Waltje, A. and Katona, A. and Goodhall, L. and Eggleston, R. and Kuo, S. and Bojescu, S. and Bule, S. and Kessler, N. and Lasalle, E. and Whitley, K. and Seaquist, E.R. and Bantle, A. and Harindhanavudhi, T. and Kumar, A. and Redmon, B. and Bantle, J. and Coe, M. and Mech, M. and Taddese, A. and Lesne, L. and Smith, S. and Kuechenmeister, L. and Shivaswamy, V. and Burbach, S. and Rodriguez, M.G. and Seipel, K. and Alfred, A. and Morales, A.L. and Eggert, J. and Lord, G. and Taylor, W. and Tillson, R. and Adolphe, A. and Burge, M. and Duran-Valdez, E. and Martinez, J. and Bancroft, A. and Kunkel, S. and Ali, Jamaleddin Ahmad F. and Hernandez, McGinnis D. and Pucchetti, B. and Scripsick, E. and Zamorano, A. and Defronzo, R.A. and Cersosimo, E. and Abdul-Ghani, M. and Triplitt, C. and Juarez, D. and Mullen, M. and Garza, R.I. and Verastiqui, H. and Wright, K. and Puckett, C. and Raskin, P. and Rhee, C. and Abraham, S. and Jordan, L.F. and Sao, S. and Morton, L. and Smith, O. and Osornio, Walker L. and Schnurr-Breen, L. and Ayala, R. and Kreymer, R.B. and Sturgess, D. and Kahn, S.E. and Alarcon-Casas, Wright L. and Boyko, E.J. and Tsai, E.C. and Trence, D.L. and Trikudanathan, S. and Fattaleh, B.N. and Montgomery, B.K. and Atkinson, K.M. and Kozedub, A. and Concepcion, T. and Moak, C. and Prikhodko, N. and Rhothisen, S. and Elasy, T.A. and Martin, S. and Shackelford, L. and Goidel, R. and Hinkle, N. and Lovell, C. and Myers, J. and Lipps, Hogan J. and McGill, J.B. and Salam, M. and Schweiger, T. and Kissel, S. and Recklein, C. and Clifton, M.J. and Tamborlane, W. and Camp, A. and Gulanski, B. and Pham, K. and Alguard, M. and Gatcomb, P. and Lessard, K. and Perez, M. and Iannone, L. and Magenheimer, E. and Montosa, A. and Cefalu, W.T. and Fradkin, J. and Burch, H.B. and Bremer, A.A. and Nathan, D.M. and Lachin, J.M. and Buse, J.B. and Kahn, S.E. and Larkin, M.E. and Tiktin, M. and Wexler, D. and Burch, H.B. and Bremer, A.A. and Lachin, J.M. and Bebu, I. and Butera, N. and Buys, C.J. and Fagan, A. and Gao, Y. and Gramzinski, M.R. and Hall, S.D. and Kazemi, E. and Legowski, E. and Liu, H. and Suratt, C. and Tripputi, M. and Arey, A. and Backman, M. and Bethepu, J. and Lund, C. and Mangat, Dhaliwal P. and McGee, P. and Mesimer, E. and Ngo, L. and Steffes, M. and Seegmiller, J. and Saenger, A. and Arends, V. and Gabrielson, D. and Conner, T. and Warren, S. and Day, J. and Huminik, J. and Soliman, E.Z. and Zhang, Z.M. and Campbell, C. and Hu, J. and Keasler, L. and Hensley, S. and Li, Y. and Herman, W.H. and Kuo, S. and Martin, C. and Waltje, A. and Mihalcea, R. and Min, D.J. and Perez-Rosas, V. and Prosser, L. and Resnicow, K. and Ye, W. and Shao, H. and Zhang, P. and Luchsinger, J. and Sanchez, D. and Assuras, S. and Groessl, E. and Sakha, F. and Chong, H. and Hillery, N. and Abdouch, I. and Bahtiyar, G. and Brantley, P. and Broyles, F.E. and Canaris, G. and Copeland, P. and Craine, J.J. and Fein, W.L. and Gliwa, A. and Hope, L. and Lee, M.S. and Meiners, R. and Meiners, V. and O'Neal, H. and Park, J.E. and Sacerdote, A. and Sledge, E. Jr and Soni, L. and Steppel-Reznik, J. and Turchin, A. and the, GRADE Study Research Group}, doi = {10.1161/CIRCULATIONAHA.123.066604}, journal-iso = {CIRCULATION}, journal = {CIRCULATION}, volume = {149}, unique-id = {34774113}, issn = {0009-7322}, abstract = {BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). METHODS: A total of 5047 participants with a mean±SD age of 57.2±10.0 years, type 2 diabetes duration of 4.0±2.7 years, and low baseline prevalence of cardiovascular disease (myocardial infarction, 5.1%; cerebrovascular accident, 2.0%) were followed for a median of 5 years. Prespecified outcomes included between-group time-to-first event analyses of MACE-3 (composite of major adverse cardiovascular events: cardiovascular death, myocardial infarction, and stroke), MACE-4 (MACE-3+unstable angina requiring hospitalization or revascularization), MACE-5 (MACE-4+coronary revascularization), MACE-6 (MACE-5+hospitalization for heart failure), and the individual components. MACE outcomes and hospitalization for heart failure in the liraglutide-treated group were compared with the other groups combined using Cox proportional hazards models. MACE-6 was also analyzed as recurrent events using a proportional rate model to compare all treatment groups. RESULTS: We observed no statistically significant differences in the cumulative incidence of first MACE-3, MACE-4, MACE-5, or MACE-6, or their individual components, by randomized treatment group. However, when compared with the other treatment groups combined, the liraglutide-treated group had a significantly lower risk of MACE-5 (adjusted hazard ratio, 0.70 [95% CI, 0.54-0.91]; P=0.021), MACE-6 (adjusted hazard ratio, 0.70 [95% CI, 0.55-0.90]; P=0.021), and hospitalization for heart failure (adjusted hazard ratio, 0.49 [95% CI, 0.28-0.86]; P=0.022). Compared with the liraglutide group, significantly higher rates of recurrent MACE-6 events occurred in the groups treated with glimepiride (rate ratio, 1.61 [95% CI, 1.13-2.29]) or sitagliptin (rate ratio 1.75; [95% CI, 1.24-2.48]). CONCLUSIONS: This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01794143. © 2024 Lippincott Williams and Wilkins. All rights reserved.}, keywords = {Blood Pressure; Aged; Adult; Female; Male; ARTICLE; human; diabetes mellitus; comparative study; smoking; disease duration; major clinical study; cohort analysis; GLYCEMIC CONTROL; GLUCOSE; information processing; hospitalization; cerebrovascular accident; heart failure; cardiovascular diseases; cholesterol; albumin; dyslipidemia; triacylglycerol; high density lipoprotein cholesterol; outcome assessment; hemoglobin A1c; creatinine; kidney disease; low density lipoprotein cholesterol; heart infarction; clinical effectiveness; antilipemic agent; non insulin dependent diabetes mellitus; coronary artery bypass graft; Revascularization; Data extraction; Liraglutide; Estimated glomerular filtration rate; New York Heart Association class; Data availability; cardiovascular disease assessment; GRADE approach; Program effectiveness; sodium glucose cotransporter 1 inhibitor}, year = {2024}, eissn = {1524-4539}, pages = {993-1003} } @article{MTMT:34799345, title = {New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration}, url = {https://m2.mtmt.hu/api/publication/34799345}, author = {Gribkova, I.V.}, doi = {10.20996/1819-6446-2024-2954}, journal-iso = {RATIONAL PHARMACOTHERAPY CARDIOLOGY}, journal = {RATIONAL PHARMACOTHERAPY IN CARDIOLOGY / RATSIONAL'NAYA FARMAKOTERAPIYA V KARDIOLOGII}, volume = {20}, unique-id = {34799345}, issn = {1819-6446}, year = {2024}, eissn = {2225-3653}, pages = {63-68} } @article{MTMT:34170050, title = {Assessment and management of heart failure in patients with chronic kidney disease}, url = {https://m2.mtmt.hu/api/publication/34170050}, author = {Guaricci, A.I. and Sturdà, F. and Russo, R. and Basile, P. and Baggiano, A. and Mushtaq, S. and Fusini, L. and Fazzari, F. and Bertandino, F. and Monitillo, F. and Carella, M.C. and Simonini, M. and Pontone, G. and Ciccone, M.M. and Grandaliano, G. and Vezzoli, G. and Pesce, F.}, doi = {10.1007/s10741-023-10346-x}, journal-iso = {HEART FAIL REV}, journal = {HEART FAILURE REVIEWS}, volume = {29}, unique-id = {34170050}, issn = {1382-4147}, year = {2024}, eissn = {1573-7322}, pages = {379-394} } @article{MTMT:34502114, title = {Costs of care and financial hardship among patients with heart failure}, url = {https://m2.mtmt.hu/api/publication/34502114}, author = {Gunn, A.H. and Warraich, H.J. and Mentz, R.J.}, doi = {10.1016/j.ahj.2023.12.001}, journal-iso = {AM HEART J}, journal = {AMERICAN HEART JOURNAL}, volume = {269}, unique-id = {34502114}, issn = {0002-8703}, abstract = {With the implementation of new therapies, more patients are living with heart failure (HF) as a chronic condition. Alongside these advances, out-of-pocket (OOP) medical costs have increased, and patients experience significant financial burden. Despite increasing interest in understanding and mitigating financial burdens, there is a relative paucity of data specific to HF. Here, we explore financial hardship in HF from the patient perspective, including estimated OOP costs for guideline-directed medical therapy for HF with reduced ejection fraction, hospitalizations, and total direct medical costs, as well as the consequences of high OOP costs. Studies estimate that high OOP costs are common in HF, and a large proportion are related to prescription drugs. Subsequently, the effects on patients can lead to worsening adherence, delayed care, and poor outcomes, leading to a financial toxicity spiral. Further, we summarize patients’ cost preferences and outline future research that is needed to develop evidence-based solutions to reduce costs in HF. © 2023 Elsevier Inc.}, year = {2024}, eissn = {1097-6744}, pages = {94-107} } @article{MTMT:34816479, title = {Guideline for the management of diabetes mellitus in the elderly in China (2024 edition)}, url = {https://m2.mtmt.hu/api/publication/34816479}, author = {Guo, L. and Xiao, X.}, doi = {10.3760/cma.j.cn115791-20240112-00020}, journal-iso = {CHINESE J DIABET MELLITUS}, journal = {CHINESE JOURNAL OF DIABETES MELLITUS}, volume = {16}, unique-id = {34816479}, issn = {1674-5809}, keywords = {Aged; ARTICLE; human; diabetes mellitus; CHINA; practice guideline; managed care}, year = {2024}, pages = {147-189} } @article{MTMT:34816478, title = {Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)}, url = {https://m2.mtmt.hu/api/publication/34816478}, author = {Guo, L. and Xiao, X.}, doi = {10.1002/agm2.12294}, journal-iso = {AGING MED}, journal = {AGING MEDICINE}, volume = {7}, unique-id = {34816478}, abstract = {With the deepening of aging in China, the prevalence of diabetes in older people has increased noticeably, and standardized diabetes management is critical for improving clinical outcomes of diabetes in older people. In 2021, the National Center of Gerontology, Chinese Society of Geriatrics, and Diabetes Professional Committee of Chinese Aging Well Association organized experts to write the first guideline for diabetes diagnosis and treatment in older people in China, the Guideline for the Management of Diabetes Mellitus in the Elderly in China (2021 Edition). The guideline emphasizes that older patients with diabetes are a highly heterogeneous group requiring comprehensive assessment and stratified and individualized management strategies. The guideline proposes simple treatments and de-intensified treatment strategies for older patients with diabetes. This edition of the guideline provides clinicians with practical and operable clinical guidance, thus greatly contributing to the comprehensive and full-cycle standardized management of older patients with diabetes in China and promoting the extensive development of clinical and basic research on diabetes in older people and related fields. In the past 3 years, evidence-based medicine for older patients with diabetes and related fields has further advanced, and new treatment concepts, drugs, and technologies have been developed. The guideline editorial committee promptly updated the first edition of the guideline and compiled the Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition). More precise management paths for older patients with diabetes are proposed, for achieving continued standardization of the management of older Chinese patients with diabetes and improving their clinical outcomes. © 2024 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd.}, keywords = {Aged; INFECTION; ARTICLE; DIABETIC NEUROPATHY; Neuropathic pain; human; diabetes mellitus; clinical feature; VACCINE; GLYCEMIC CONTROL; INSULIN; hypoglycemia; Sleep Apnea Syndromes; sleep disorder; injection; CHINA; Comorbidity; Primary Prevention; heart failure; Diabetes; risk management; blood glucose monitoring; insulin treatment; diabetic nephropathy; hyperglycemia; insulin dependent diabetes mellitus; hypotension; disease classification; lactic acidosis; palliative therapy; GUIDELINES; osteoporosis; neoplasm; geriatric patient; mental disease; vaccination; Screening; Prophylaxis; health education; practice guideline; cognitive defect; diet therapy; evidence based medicine; eye fundus; clinical evaluation; mouth disease; non insulin dependent diabetes mellitus; home care; skin disease; lifestyle modification; dipeptidyl peptidase IV inhibitor; alpha glucosidase inhibitor; 2,4 thiazolidinedione derivative; metformin; Clinical outcome; sulfonylurea derivative; repaglinide; nateglinide; diabetic patient; polypharmacy; kinesiotherapy; Cardiovascular risk factor; nursing home; Perioperative Care; secondary prevention; falling; Chinese medicine; Geriatric assessment; glucagon like peptide 1 receptor agonist; Tertiary Prevention; hospital management; Sarcopenia; Frailty; combination drug therapy; Peripheral arterial disease; lower limb; diabetic complication; Diabetic Foot; Sodium glucose cotransporter 2 inhibitor; clinician; Diabetic eye disease; the older adults}, year = {2024}, eissn = {2475-0360}, pages = {5-51} } @article{MTMT:34742563, title = {Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial}, url = {https://m2.mtmt.hu/api/publication/34742563}, author = {Hadjadj, S. and Cooper, M.E. and Steubl, D. and Petrini, M. and Hantel, S. and Mattheus, M. and Wanner, C. and Thomas, M.C.}, doi = {10.1016/j.xkme.2023.100783}, journal-iso = {Kidney Med}, journal = {KIDNEY MEDICINE}, volume = {6}, unique-id = {34742563}, abstract = {Rationale & Objective: Kidney function progressively declines in most patients with type 2 diabetes (T2DM). Many develop progressive chronic kidney disease (CKD), but some experience a more rapid decline, with a greater risk of kidney failure and cardiovascular disease. In EMPA-REG OUTCOME, empagliflozin was associated with slower kidney disease progression. This post hoc analysis evaluated the effect of empagliflozin (pooled doses) on the prevalence of a “rapid decliner” phenotype, defined by an annual estimated glomerular filtration rate (eGFR) decline of >3 mL/min/1.73 m2. Study Design: This was an exploratory analysis of EMPA-REG OUTCOME, a large randomized, double-blind, placebo-controlled trial in adults with T2DM, established cardiovascular disease and an eGFR of ≥30 mL/min/1.73 m2. Setting & Participants: Analysis was undertaken on 6,967 participants (99.2%) in whom serial eGFR data was available. Interventions: Patients were randomized (1:1:1) to empagliflozin 10 mg, 25 mg, or placebo in addition to standard of care. Outcomes: Annual change in eGFR over the maintenance phase of treatment (week 4 to last value on treatment) was calculated using linear regression models. Logistic regression analysis was used to investigate differences in rapid decline between the treatment groups. Results: Over the study period, a rapid decliner phenotype was observed in 188 (9.5%) participants receiving placebo and 134 (3.4%) receiving empagliflozin. After adjusting for other risk factors, this equated to a two-third reduction in odds (OR, 0.32; 95% CI, 0.25-0.40; P < 0.001) among participants receiving empagliflozin versus placebo. A comparable risk reduction was observed using a threshold of eGFR decline of >5 mL/min/1.73 m2/y (empagliflozin vs placebo, 43 [1.1%] vs 44 [2.2%] participants; OR, 0.47; 95% CI, 0.31-0.72; P < 0.001). Limitations: This is a post hoc analysis of a trial undertaken in participants with T2DM and CVD. Generalization of findings to other settings remains to be established. Conclusions: Patients receiving empagliflozin were significantly less likely to experience a rapid decline in eGFR over a median of 2.6 years of exposure to the study drug. Funding: The Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. Trial Registration: clinicaltrials.gov ID: NCT01131676 Plain-Language Summary: In most people with type 2 diabetes, their kidney function starts to decline over time. However, in some people, this can happen more rapidly, which can increase their risk of kidney or cardiovascular disease. A major study, EMPA-REG OUTCOME, has shown that empagliflozin, which helps to control blood sugar in people with type 2 diabetes, also reduced the risk of cardiovascular disease events and slowed the progression of kidney disease, when compared with people in the study who received placebo. In this new research from the same major study empagliflozin, compared with a placebo, was shown to reduce the risk of people having a rapid decline in their kidney function over the 3 years of the study. © 2023 The Authors}, keywords = {Adult; Female; Middle Aged; Male; ARTICLE; human; diabetes mellitus; Treatment Outcome; Incidence; risk factor; major clinical study; controlled study; clinical feature; dose response; drug effect; randomized controlled trial; cardiovascular disease; drug safety; drug efficacy; double blind procedure; chronic kidney disease; randomized controlled trials; follow up; kidney function; maintenance therapy; risk reduction; clinical effectiveness; adverse outcome; acute kidney failure; non insulin dependent diabetes mellitus; kidney dysfunction; exploratory research; Estimated glomerular filtration rate; Estimated glomerular filtration rate; Empagliflozin}, year = {2024}, eissn = {2590-0595} } @article{MTMT:34694316, title = {Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial}, url = {https://m2.mtmt.hu/api/publication/34694316}, author = {Harrington, J. and Mentz, R.J. and Rockhold, F.W. and Garg, J. and Butler, J. and De, Pasquale C.G. and Ezekowitz, J.A. and Lewis, G.D. and O’Meara, E. and Ponikowski, P. and Troughton, R.W. and Wong, Y.W. and Adamczyk, R. and Storie, T. and Blackman, N. and Hernandez, A.F.}, doi = {10.1161/CIRCHEARTFAILURE.123.010676}, journal-iso = {CIRC-HEART FAIL}, journal = {CIRCULATION-HEART FAILURE}, volume = {17}, unique-id = {34694316}, issn = {1941-3289}, year = {2024}, eissn = {1941-3297}, pages = {169-177} } @article{MTMT:34323200, title = {Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia}, url = {https://m2.mtmt.hu/api/publication/34323200}, author = {Harris, D.D. and Sabe, S.A. and Xu, C.M. and Sabra, M. and Broadwin, M. and Malhotra, A. and Li, J.W. and Abid, M.R. and Sellke, F.W.}, doi = {10.1016/j.surg.2023.09.043}, journal-iso = {SURGERY (UNITED STATES)}, journal = {SURGERY}, volume = {175}, unique-id = {34323200}, issn = {0039-6060}, abstract = {Background: Inflammation and disruption of cardiac metabolism are prevalent in the setting of myocardial ischemia. Canagliflozin, a sodium-glucose costransporter-2 inhibitor, has beneficial effects on the heart, though the precise mechanisms are unknown. This study investigated the effects of canagliflozin therapy on metabolic pathways and inflammation in ischemic myocardial tissue using a swine model of chronic myocardial ischemia. Methods: Sixteen Yorkshire swine underwent placement of an ameroid constrictor to the left circumflex artery to induce chronic ischemia. Two weeks later, pigs received either no drug (n = 8) or 300 mg canagliflozin (n = 8) daily. Five weeks later, pigs underwent terminal harvest and tissue collection. Results: Canagliflozin treatment was associated with a trend toward decreased expression of fatty acid oxidation inhibitor acetyl-CoA carboxylase and decreased phosphorylated/inactivated acetyl-CoA carboxylase, a promotor of fatty acid oxidation, compared with control ischemic myocardium (P =.08, P =.03). There was also a significant modulation in insulin resistance markers p-IRS1, p-PKCα, and phosphoinositide 3-kinase in ischemic myocardium of the canagliflozin group compared with the control group (all P <.05). Canagliflozin treatment was associated with a significant increase in inflammatory markers interleukin 6, interleukin 17, interferon-gamma, and inducible nitric oxide synthase (all P <.05). There was a trend toward decreased expression of the anti-inflammatory cytokines interleukin 10 (P =.16) and interleukin 4 (P =.31) with canagliflozin treatment. Conclusion: The beneficial effects of canagliflozin therapy appear to be associated with inhibition of fatty acid oxidation and enhancement of insulin signaling in ischemic myocardium. Interestingly, canagliflozin appears to increase the levels of several inflammatory markers, but further studies are required to better understand how canagliflozin modulates inflammatory signaling pathways. © 2023 Elsevier Inc.}, year = {2024}, pages = {265-270} } @article{MTMT:34777751, title = {SGLT2 inhibitors: Beyond glycemic control}, url = {https://m2.mtmt.hu/api/publication/34777751}, author = {Hasan, I. and Rashid, T. and Jaikaransingh, V. and Heilig, C. and Abdel-Rahman, E.M. and Awad, A.S.}, doi = {10.1016/j.jcte.2024.100335}, journal-iso = {J Clin Transl Endocrinol}, journal = {Journal of Clinical and Translational Endocrinology}, volume = {35}, unique-id = {34777751}, issn = {2214-6237}, year = {2024} } @article{MTMT:34741073, title = {A csökkent ejekciós frakcióval járó krónikus szívelégtelenség gyógyszeres terápiája: vericiguát, a lehetséges ötödik pillér?}, url = {https://m2.mtmt.hu/api/publication/34741073}, author = {Hepp, Tamás and Varjas, Norbert and Hévízi, Zsombor and Bodor, Alexandra and Benczúr, Béla}, doi = {10.33616/lam.34.0008}, journal-iso = {LEGE ART MED}, journal = {LEGE ARTIS MEDICINAE}, volume = {34}, unique-id = {34741073}, issn = {0866-4811}, abstract = {A krónikus szívelégtelenség incidenciája és prevalenciája világszerte növekszik, morbiditása és mortalitása továbbra is magas, a betegség megfelelő kezelése kiemelt jelentőségű. A csökkent balkamra-funkcióval járó szívelégtelenség (HFrEF) kezelése jelenleg négy alappillérre támaszkodik: ACEI/ARNI, β-blokkolók, MRA-k és legújabb csoportként az SGLT-2-gátlók, melyek mind - egyike igazoltan csökkenti a HFrEF-betegek mortalitását és morbiditását. A HFrEF gyógyszeres terápiájának viszonylag új terápiás lehetősége a szolúbilis guanilát-cikláz-stimulátor vericiguát, mely a szívelégtelenségben szenvedő betegekben károsodott NO-sGC-cGMP jelátviteli útba avatkozik be. A vericiguát nitrogén-monoxid jelenlététől függetlenül aktiválja a sGC enzimet, melynek következtében az intracelluláris cGMP-szint magas marad, amely javíthatja az endothelialis, myocardialis és vascularis funkciókat egyaránt. A vericiguát biztonságosságát és hatékonyságát a VICTORIA vizsgálatban igazolták. A közelmúltban szív elégtelenség miatt kórházba került, vagy parenteralis diuretikumterápiára szoruló, 45%-nál rosszabb ejekciós frakcióval járó krónikus szívelégtelen betegekben a vericiguát szignifikáns mértékben csökkentette a szívelégtelenség miatti hospitalizáció és a cardiovascularis halálozás összetett vég pontját placebóhoz képest. A relatívkockázat-csökkenés 10%, az abszolútkockázat-csökkenés 4,2% volt a vericiguát-csoportban. A VICTORIA vizsgálatban mutatott pozitív eredményeknek köszönhetően a vericiguát új gyógyszeres terápiás lehetőségként került be a 2021-ben bemutatott ESC Szívelégtelenség irányelvbe. Az ajánlás jelenleg IIb evidenciaszinttel javasolja a vericiguát alkalmazását olyan HFrEF-betegek esetén, akik a közelmúltban optimális gyógyszeres terápia ellenére szívelégtelenség progressziója miatt ellátásra szorultak.}, year = {2024}, eissn = {2063-4161}, pages = {8-15} } @article{MTMT:34649636, title = {A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)}, url = {https://m2.mtmt.hu/api/publication/34649636}, author = {Hirota, Yushi and Kakei, Yasumasa and Imai, Junta and Katagiri, Hideki and Ebihara, Ken and Wada, Jun and Suzuki, Junichi and Urakami, Tatsuhiko and Omori, Takashi and Ogawa, Wataru}, doi = {10.1007/s13300-023-01526-x}, journal-iso = {DIABTHERAP}, journal = {DIABETES THERAPY}, volume = {15}, unique-id = {34649636}, issn = {1869-6953}, keywords = {Empagliflozin; SGLT2 inhibitor; Type B insulin resistance syndrome; Genetic insulin resistance syndrome; Lipoatrophic diabetes; Type A insulin resistance syndrome}, year = {2024}, eissn = {1869-6961}, pages = {533-545} } @article{MTMT:34603292, title = {Are you giving men with heart failure the best care?}, url = {https://m2.mtmt.hu/api/publication/34603292}, author = {Hogan, George and Patel, Hiten and Patel, Nikhil R.}, doi = {10.1002/tre.948}, journal-iso = {TRENDS IN UROLOGY & MENS HEALTH}, journal = {TRENDS IN UROLOGY & MENS HEALTH}, volume = {15}, unique-id = {34603292}, issn = {2044-3730}, abstract = {Heart failure is a leading cause of morbidity and mortality worldwide. Management involves a comprehensive multidisciplinary approach focusing on symptom control, preventing disease progression and improving patients' quality of life. Significant advances in recent years, including the introduction of combination angiotensin receptor-neprilysin inhibitors and sodium-glucose co-transporter 2 inhibitors, have led to an improvement in long-term prognosis.}, year = {2024}, eissn = {2044-3749}, pages = {11-16} } @article{MTMT:34795677, title = {Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet}, url = {https://m2.mtmt.hu/api/publication/34795677}, author = {Hojná, S. and Malínská, H. and Hüttl, M. and Vaňourková, Z. and Marková, I. and Miklánková, D. and Hrdlička, J. and Papoušek, F. and Neckář, J. and Kujal, P. and Behuliak, M. and Rauchová, H. and Kadlecová, M. and Sedmera, D. and Neffeová, K. and Zábrodská, E. and Olejníčková, V. and Zicha, J. and Vaněčková, I.}, doi = {10.1016/j.biopha.2024.116520}, journal-iso = {BIOMED PHARMACOTHER}, journal = {BIOMEDICINE & PHARMACOTHERAPY}, volume = {174}, unique-id = {34795677}, issn = {0753-3322}, abstract = {A combination of liver and heart dysfunction worsens the prognosis of human survival. The aim of this study was to investigate whether empagliflozin (a sodium-glucose transporter-2 inhibitor) has beneficial effects not only on cardiac and renal function but also on hepatic function. Adult (6-month-old) male spontaneously hypertensive rats (SHR) were fed a high-fat diet (60% fat) for four months to induce hepatic steatosis and mild heart failure. For the last two months, the rats were treated with empagliflozin (empa, 10 mg.kg-1.day-1 in the drinking water). Renal function and oral glucose tolerance test were analyzed in control (n=8), high-fat diet (SHR+HF, n=10), and empagliflozin-treated (SHR+HF+empa, n=9) SHR throughout the study. Metabolic parameters and echocardiography were evaluated at the end of the experiment. High-fat diet feeding increased body weight and visceral adiposity, liver triglyceride and cholesterol concentrations, and worsened glucose tolerance. Although the high-fat diet did not affect renal function, it significantly worsened cardiac function in a subset of SHR rats. Empagliflozin reduced body weight gain but not visceral fat deposition. It also improved glucose sensitivity and several metabolic parameters (plasma insulin, uric acid, and HDL cholesterol). In the liver, empagliflozin reduced ectopic lipid accumulation, lipoperoxidation, inflammation and pro-inflammatory HETEs, while increasing anti-inflammatory EETs. In addition, empagliflozin improved cardiac function (systolic, diastolic and pumping) independent of blood pressure. The results of our study suggest that hepatoprotection plays a decisive role in the beneficial effects of empagliflozin in preventing the progression of cardiac dysfunction induced by high-fat diet feeding. © 2024 The Authors}, keywords = {kidney function; metabolic parameters; liver steatosis; Cardiac function; SGLT-2 inhibition}, year = {2024}, eissn = {1950-6007} } @article{MTMT:34795719, title = {Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia}, url = {https://m2.mtmt.hu/api/publication/34795719}, author = {Horiuchi, Y. and Asami, M. and Yahagi, K. and Oshima, A. and Gonda, Y. and Yoshiura, D. and Komiyama, K. and Yuzawa, H. and Tanaka, J. and Aoki, J. and Tanabe, K.}, doi = {10.3390/jcm13061670}, journal-iso = {J CLIN MED}, journal = {JOURNAL OF CLINICAL MEDICINE}, volume = {13}, unique-id = {34795719}, abstract = {(1) Background: In patients with heart failure (HF) and impaired nutritional status or decreased muscle mass, sodium-glucose cotransporter-2 inhibitors (SGLT2is) may worsen these conditions and result in poor prognosis, especially worsening of frailty. We aimed to investigate the relationship between SGLT2is and clinical outcomes, including frailty-related events, in patients with HF and malnutrition, frailty, sarcopenia, or cachexia. (2) Methods: In this retrospective observational cohort study, a global federated health research network provided data on patients with HF and malnutrition, frailty, sarcopenia, or cachexia from January 2016 to December 2021. We investigated the incidence of the composite endpoint of death or frailty-related events within one year. (3) Results: Among 214,778 patients included in the analysis, 4715 were treated with SGLT2is. After propensity score matching, 4697 patients in the SGLT2is group were matched with 4697 patients in the non-SGLT2is groups. The incidence of the composite endpoint, mortality, and frailty-related events was lower in the SGLT2is group than in the non-SGLT2is group (composite endpoint, 65.6% versus 77.6%, p < 0.001; mortality, 17.4% vs. 35.5%, p < 0.001; frailty-related events, 59.4% vs. 64.3%, p < 0.001). (4) Conclusions: Patients with HF and malnutrition, frailty, sarcopenia, or cachexia had a high incidence of death and frailty-related events. SGLT2is were associated with a lower incidence of these events. © 2024 by the authors.}, keywords = {heart failure; malnutrition; cachexia; Sarcopenia; Frailty; sodium-glucose cotransporter-2 inhibitors}, year = {2024}, eissn = {2077-0383} } @article{MTMT:34742622, title = {The expert consensus on care and education for patients with diabetic kidney disease in Taiwan}, url = {https://m2.mtmt.hu/api/publication/34742622}, author = {Hsu, C.-Y. and Yeh, C.-Y. and Yen, T.-Y. and Chen, C.-C. and Chen, J.-F. and Chu, C.-H. and Huang, C.-N. and Lin, C.-L. and Lin, S.-Y. and Liu, F.-H. and Ou, H.-Y. and Wang, C.-Y.}, doi = {10.1016/j.pcd.2024.02.003}, journal-iso = {PRIM CARE DIABETES}, journal = {PRIMARY CARE DIABETES}, volume = {In press}, unique-id = {34742622}, issn = {1751-9918}, abstract = {Increasing prevalence of type 2 DM (T2DM) and diabetic kidney disease (DKD) has posed a great impact in Taiwan. However, guidelines focusing on multidisciplinary patient care and patient education remain scarce. By literature review and expert discussion, we propose a consensus on care and education for patients with DKD, including general principles, specifics for different stages of chronic kidney disease (CKD), and special populations. (i.e. young ages, patients with atherosclerotic cardiovascular disease or heart failure, patients after acute kidney injury, and kidney transplant recipients). Generally, we suggest performing multidisciplinary patient care and education in alignment with the government-led Diabetes Shared Care Network to improve the patients’ outcomes for all patients with DKD. Also, close monitoring of renal function with early intervention, control of comorbidities in early stages of CKD, and nutrition adjustment in advanced CKD should be emphasized. © 2024 The Authors}, keywords = {Diabetic kidney disease; Type 2 DM; Diabetes shared care network}, year = {2024}, eissn = {1878-0210} } @article{MTMT:34766721, title = {Effectiveness and safety of empagliflozin: final results from the EMPRISE study}, url = {https://m2.mtmt.hu/api/publication/34766721}, author = {Htoo, P.T. and Tesfaye, H. and Schneeweiss, S. and Wexler, D.J. and Everett, B.M. and Glynn, R.J. and Schmedt, N. and Koeneman, L. and Déruaz-Luyet, A. and Paik, J.M. and Patorno, E.}, doi = {10.1007/s00125-024-06126-3}, journal-iso = {DIABETOLOGIA}, journal = {DIABETOLOGIA}, volume = {In press}, unique-id = {34766721}, issn = {0012-186X}, abstract = {Aims/hypothesis: Limited evidence exists on the comparative safety and effectiveness of empagliflozin against alternative glucose-lowering medications in individuals with type 2 diabetes with the broad spectrum of cardiovascular risk. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) cohort study was designed to monitor the safety and effectiveness of empagliflozin periodically for a period of 5 years with data collection from electronic healthcare databases. Methods: We identified individuals ≥18 years old with type 2 diabetes who initiated empagliflozin or dipeptidyl peptidase-4 inhibitors (DPP-4i) from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we identified four a priori-defined effectiveness outcomes: (1) myocardial infarction (MI) or stroke; (2) hospitalisation for heart failure (HHF); (3) major adverse cardiovascular events (MACE); and (4) cardiovascular mortality or HHF. Safety outcomes included lower-limb amputations, non-vertebral fractures, diabetic ketoacidosis (DKA), acute kidney injury (AKI), severe hypoglycaemia, retinopathy progression, and short-term kidney and bladder cancers. We estimated HRs and rate differences (RDs) per 1000 person-years, overall and stratified by age, sex, baseline atherosclerotic cardiovascular disease (ASCVD) and heart failure. Results: We identified 115,116 matched pairs. Compared with DPP-4i, empagliflozin was associated with lower risks of MI/stroke (HR 0.88 [95% CI 0.81, 0.96]; RD −2.08 [95% CI (−3.26, −0.90]), HHF (HR 0.50 [0.44, 0.56]; RD −5.35 [−6.22, −4.49]), MACE (HR 0.73 [0.62, 0.86]; RD −6.37 [−8.98, −3.77]) and cardiovascular mortality/HHF (HR 0.57 [0.47, 0.69]; RD −10.36 [−12.63, −8.12]). Absolute benefits were larger in older individuals and in those with ASCVD/heart failure. Empagliflozin was associated with an increased risk of DKA (HR 1.78 [1.44, 2.19]; RD 1.59 [1.08, 2.09]); decreased risks of AKI (HR 0.62 [0.54, 0.72]; RD −2.39 [−3.08, −1.71]), hypoglycaemia (HR 0.75 [0.67, 0.84]; RD −2.46 [−3.32, −1.60]) and retinopathy progression (HR 0.78 [0.63, 0.96)]; RD −9.49 [−16.97, −2.10]); and similar risks of other safety events. Conclusions/interpretation: Empagliflozin relative to DPP-4i was associated with risk reductions of MI or stroke, HHF, MACE and the composite of cardiovascular mortality or HHF. Absolute risk reductions were larger in older individuals and in those who had history of ASCVD or heart failure. Regarding the safety outcomes, empagliflozin was associated with an increased risk of DKA and lower risks of AKI, hypoglycaemia and progression to proliferative retinopathy, with no difference in the short-term risks of lower-extremity amputation, non-vertebral fractures, kidney and renal pelvis cancer, and bladder cancer. Graphical Abstract: (Figure presented.) © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.}, keywords = {heart failure; cardiovascular diseases; type 2 diabetes mellitus; Empagliflozin; SGLT2i; DPP-4i}, year = {2024}, eissn = {1432-0428}, pages = {In press} } @article{MTMT:34777755, title = {Effects of SGLT2 Inhibitors with and without Metformin in High-Risk, Treatment-Naïve Patients with Diabetes}, url = {https://m2.mtmt.hu/api/publication/34777755}, author = {Huang, C.-Y. and Lee, J.-K.}, doi = {10.3390/jcm13051387}, journal-iso = {J CLIN MED}, journal = {JOURNAL OF CLINICAL MEDICINE}, volume = {13}, unique-id = {34777755}, year = {2024}, eissn = {2077-0383} } @article{MTMT:34536402, title = {Cost-Effectiveness of New Quadruple Therapy Compared with Standard Treatment for Patients with Heart Failure in China}, url = {https://m2.mtmt.hu/api/publication/34536402}, author = {Huang, Y. and Zhou, H. and Fang, C. and Ma, L. and Zhang, Y. and Rong, W. and Liu, X. and Ye, H.}, doi = {10.1097/FJC.0000000000001476}, journal-iso = {J CARDIOVASC PHARM}, journal = {JOURNAL OF CARDIOVASCULAR PHARMACOLOGY}, volume = {83}, unique-id = {34536402}, issn = {0160-2446}, abstract = {Abstract:This study aimed to compare the cost-effectiveness of the new quadruple therapy regimen of adding sodium-glucose-linked transporter 2 (SGLT2) inhibitors, with standard treatment for patients with heart failure (HF) in China. From the payer's perspective, the dates of cardiovascular event recurrences were extracted from a meta-analysis including 6 trials, combined with the treatment cost for patients with HF in China to construct a Markov model. The outcomes included per capita medical costs and incremental cost-effectiveness ratio, using quality-adjusted life years (QALYs) data. Single-factor, probability sensitivity analysis, and scenario analysis were used to explore the potential uncertainties of the model. The per capita costs of the new quadruple therapy regimen and standard treatment were $87441.26 and $87087.54, respectively. The new regimen was associated with a mean of 21.44 QALYs gained, compared with 18.60 QALYs gained with the standard treatment. The incremental cost-effectiveness ratio was $124.03 per QALY gained. The sensitivity analysis revealed that changes in the parameters within the set range did not affect the model results. In China, compared with standard treatment, the new quadruple therapy regimen with SGLT2 inhibitors reduce the frequency of cardiovascular events among patients with HF, and it has economic advantages. © 2024 Lippincott Williams and Wilkins. All rights reserved.}, keywords = {Aged; Humans; PATIENT; ARTICLE; human; diabetes mellitus; comparative study; Sensitivity analysis; CHINA; CHINA; CHINA; Monte Carlo method; Cost-Benefit Analysis; heart failure; heart failure; heart failure; heart failure; cardiovascular disease; drug cost; meta analysis; recurrent disease; event free survival; cost benefit analysis; hospital readmission; patients; cost effectiveness analysis; Clinical outcome; quality adjusted life year; Cost-effectiveness; Markov chain; very elderly; New York Heart Association class; dapagliflozin; SGLT2 inhibitors; Empagliflozin; Sodium glucose cotransporter 2 inhibitor; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; Sodium-glucose transporter 2 inhibitors; utility value; quadruple chemotherapy}, year = {2024}, eissn = {1533-4023}, pages = {86-92} } @article{MTMT:34169712, title = {Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study}, url = {https://m2.mtmt.hu/api/publication/34169712}, author = {Hu, Wei-Syun and Lin, Cheng-Li}, doi = {10.1007/s00210-023-02623-1}, journal-iso = {N-S ARCH PHARMACOL}, journal = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, volume = {397}, unique-id = {34169712}, issn = {0028-1298}, abstract = {To compare the potential role of sodium-glucose cotransporter-2 inhibitors (SGLT2I) in the development of psychiatric disease among patients with type 2 diabetes mellitus (DM). Using a large population-based database, SGLT2I users and non-SGLT2I users were 1:1 matched according to the covariates of sex, age, comorbidities, adapted diabetes complications severity index (DCSI), medications, and index year using propensity score matching and a logistic regression model. We calculated the incidence of major psychiatric disorders and adjusted hazard ratios (HR) with 95% confidence interval (CI) for SGLT2I users and the non- SGLT2I users using a Cox proportional hazards model. SGLT2I were associated with a lower risk for psychiatric disorders than those not treated with SGLT2I (HR 0.80 and 95% CI 0.72-0.88). Among patients with DM, SGLT2I were associated with a lower risk of psychiatric disease.}, keywords = {diabetes mellitus; SGLT2i; COMPLICATIONS SEVERITY INDEX; HEALTH INSURANCE ENROLLEES}, year = {2024}, eissn = {1432-1912}, pages = {575-581} } @article{MTMT:34170072, title = {Sodium-glucose cotransporter-2 inhibitor in risk of sepsis/septic shock among patients with type 2 diabetes mellitus—a retrospective analysis of nationwide medical claims data}, url = {https://m2.mtmt.hu/api/publication/34170072}, author = {Hu, W.-S. and Lin, C.-L.}, doi = {10.1007/s00210-023-02685-1}, journal-iso = {N-S ARCH PHARMACOL}, journal = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, volume = {397}, unique-id = {34170072}, issn = {0028-1298}, year = {2024}, eissn = {1432-1912}, pages = {1623-1631} } @article{MTMT:34613005, title = {The WATCH-DM risk score estimates clinical outcomes in type 2 diabetic patients with heart failure with preserved ejection fraction}, url = {https://m2.mtmt.hu/api/publication/34613005}, author = {Iwakura, Katsuomi and Onishi, Toshinari and Okamura, Atsunori and Koyama, Yasushi and Tanaka, Nobuaki and Okada, Masato and Fujii, Kenshi and Seo, Masahiro and Yamada, Takahisa and Yano, Masamichi and Hayashi, Takaharu and Yasumura, Yoshio and Nakagawa, Yusuke and Tamaki, Shunsuke and Nakagawa, Akito and Sotomi, Yohei and Hikoso, Shungo and Nakatani, Daisaku and Sakata, Yasushi and Watanabe, Tetsuya and Higuchi, Yoshiharu and Masuda, Masaharu and Asai, Mitsutoshi and Mano, Toshiaki and Fuji, Hisakazu and Masuda, Daisaku and Shutta, Ryu and Yamashita, Shizuya and Sairyo, Masami and Abe, Haruhiko and Ueda, Yasunori and Matsumura, Yasushi and Nagai, Kunihiko and Nishino, Masami and Tanouchi, Jun and Arita, Yoh and Ogasawara, Nobuyuki and Ishizu, Takamaru and Ichikawa, Minoru and Takano, Yuzuru and Rin, Eisai and Shinoda, Yukinori and Tachibana, Koichi and Hoshida, Shiro and Izumi, Masahiro and Yamamoto, Hiroyoshi and Kato, Hiroyasu and Nakatani, Kazuhiro and Yasuga, Yuji and Nishio, Mayu and Hirooka, Keiji and Yoshimura, Takahiro and Kashiwase, Kazunori and Hasegawa, Shinji and Tani, Akihiro and Okumoto, Yasushi and Makino, Yasunaka and Kijima, Yoshiyuki and Kitao, Takashi and Fujita, Masashi and Harada, Koichiro and Kumada, Masahiro and Nakagawa, Osamu and Araki, Ryo and Yamada, Takayuki and Matsuoka, Yuki and Sato, Taiki and Sunaga, Akihiro and Oeun, Bolrathanak and Kida, Hirota and Dohi, Tomoharu and Akazawa, Yasuhiro and Nakamoto, Kei and Okada, Katsuki and Sera, Fusako and Kioka, Hidetaka and Ohtani, Tomohito and Takeda, Toshihiro and Mizuno, Hiroya}, doi = {10.1038/s41598-024-52101-8}, journal-iso = {SCI REP}, journal = {SCIENTIFIC REPORTS}, volume = {14}, unique-id = {34613005}, issn = {2045-2322}, abstract = {The coexistence of heart failure is frequent and associated with higher mortality in patients with type 2 diabetes (T2DM), and its management is a critical issue. The WATCH-DM risk score is a tool to predict heart failure in patients with type 2 diabetes mellitus (T2DM). We investigated whether it could estimate outcomes in T2DM patients with heart failure with preserved ejection fraction (HFpEF). The WATCH-DM risk score was calculated in 418 patients with T2DM hospitalized for HFpEF (male 49.5%, age 80 +/- 9 years, HbA1c 6.8 +/- 1.0%), and they were divided into the äverage or lower" (<= 10 points), "high" (11-13 points) and "very high" (>= 14 points) risk groups. We followed patients to observe all-cause death for 386 days (median). We compared the area under the curve (AUC) of the WATCH-DM score for predicting 1-year mortality with that of the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score and of the Barcelona Bio-Heart Failure Risk (BCN Bio-HF). Among the study patients, 108 patients (25.8%) had average or lower risk scores, 147 patients (35.2%) had high risk scores, and 163 patients (39.0%) had very high risk scores. The Cox proportional hazard model selected the WATCH-DM score as an independent predictor of all-cause death (HR per unit 1.10, 95% CI 1.03 to 1.19), and the äverage or lower" risk group had lower mortality than the other groups (p = 0.047 by log-rank test). The AUC of the WATCH-DM for 1-year mortality was 0.64 (95% CI 0.45 to 0.74), which was not different from that of the MAGGIC score (0.72, 95% CI 0.63 to 0.80, p = 0.08) or that of BCN Bio-HF (0.70, 0.61 to 0.80, p = 0.25). The WATCH-DM risk score can estimate prognosis in T2DM patients with HFpEF and can identify patients at higher risk of mortality.}, year = {2024}, eissn = {2045-2322} }